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SYNOPSIS
1The work is incorporated in the thesis with the title "DESIGN AND
SYNTHESIS OF SOME HETEROCYCLES OF MEDICINAL
INTEREST" has been described as under.
[A] STUDIES ON PYRAZOLES
[B] STUDIES ON TRIAZOLES
[A] STUDIES ON PYRAZOLES
Pyrazo le  der ivat ives  are  assoc ia ted wi th  broad spect rum of
pharmacological activities like antitubercular, antimicrobial, hypnotics,
antiinflammatory, antitumor, plant growth regulators and are also used as
herbicidal and insecticidal.
Considering the increasing importance of pyrazole nucleus, the
synthesis of some new chalcones, pyrazolines, isoxazoles, cyanopyridines,
cyanopyridones and arylidenes bearing 1,N-phenyl-3-p-anisyl-4-formyl
pyrazole nucleus has been undertaken.
PART - I  : STUDIES ON ISOXAZOLES
Isoxazoles possess remarkable pharmacological importance and
biological activities such as antifungal, antibacterial, sedative and hypnotics
etc. In view of there facts, it appeared of interest to design and synthesise
isoxazole derivatives, which have been described as under.
SECTION - I : Synthesis and biological evaluation of 1-Aryl-3-
[1',N-phenyl-3'-p-anisyl-pyrazol-4'-yl]-2-propene-
1-ones.
Type (I) R = Aryl
N
N
O
R
O
CH3
The chalcones of type (I) have been undertaken by the condensation
of 1-phenyl-3-p-anisyl-4-formyl pyrazole with different aryl ketones in
presence of 40% KOH.
SECTION - II : Synthesis and biological evaluation of 3-Aryl-5-
[1'-N-phenyl-3'-p-anisyl-pyrazol-4'-yl]-isoxazoles
The isoxazole derivatives of type (II) have been prepared by the reaction
of chalcones of type (I) with anhydrous sodium acetate and hydroxylamine
hydrochloride in glacial acetic acid.
PART - II  : STUDIES ON PYRAZOLYLPYRAZOLINES
Pyrazol ine derivatives are associated with broad spectrum of
pharmacological activities like anticancer, anthalmentic, antitubercular,
antiinflammatory etc. In view of above findings, some new pyrazolines
bearing 1-phenyl-3-p-anisyl-4-formyl pyrazole moiety have been prepared
which have been described as under.
SECTION - I : Synthesis and biological evaluation of 3-Aryl-5-
[1',N-phenyl-3'-p-anisyl-pyrazol-4'-yl]-pyrazolines
N
N
O
CH3
NNH
R
Type (III) R = Aryl
2
N
N
O
CH3
NO
R
R = ArylType (II)
The pyrazoline derivatives of type (III) have been prepared by the
reaction of chalcones of type (I) with hydrazine hydrate.
SECTION - II : Synthesis and biological evaluation of 1,N-
Acetyl-3-aryl-5-[1',N-phenyl-3'-p-anisyl-pyrazol-
4'-yl]-pyrazolines
The pyrazoline derivatives of type (IV) have been undertaken by the
reaction of chalcones of type (I) with hydrazine hydrate in glacial acetic acid.
SECTION - III : Synthesis and biological evaluation of 1,N-
Phenyl-3-aryl-5-[1',N-phenyl-3'-p-anisyl-pyrazol-
4'-yl]-pyrazolines
The pyrazolines of type (V) have been prepared by the reaction of
chalcones of type (I) with phenyl hydrazine in presence of basic catalyst like
piperidine.
N
N
O
CH3
NN
R
CH3
O
Type (IV) R = Aryl
N
N
O
CH3
NN
R
Type (V) R = Aryl
3
PART - III  : STUDIES ON CYANOPYRIDINES
Cyanopyridine plays a vital role owing to their wide range of biological
act ivi t ies such as antihypertensive, antibacterial ,  antidiabetic and
anticholestemic. They have been also used as dyes for cotton and polyester
fabrics, it appeared of interest to design and synthesise cyanopyridine
derivatives, which have been described as under.
SECTION - I : Synthesis and biological evaluation of 2-Amino-
3-cyano-4-[1',N-phenyl-3'-p-anisyl-pyrazol-4'-yl]-
6-aryl-pyridines
2-Amino-3-cyanopyridines of type (VI) have been under taken by the
condensation of chalcones of type (I) with ammonium acetate and
malononitrile.
PART - IV  : STUDIES ON CYANOPYRIDONES
The group of  compounds containing the cyanopyridone ring system
have a prominent feature in medicinal chemistry and possess biological
activities such as analgesic, antidiabetic, anticonvulsant, insecticidal and
antibacterial etc. In view of these facts, it was contemplated to synthesise
cyanopyridone derivatives which have been described as under.
N
N
O
CH3
N
NH2
R
N
Type (VI) R = Aryl
4
SECTION - I : Synthesis and biological evaluation of 3-Cyano-
4-[1',N-phenyl-3'-p-anisyl-pyrazol-4'-yl]-6-aryl-
1,2-dihydro-2-pyridones
The cyanopyridones of type (VII) have been prepared by condensation
of chalcones of type (I) with ethylcyanoacetate and ammonium acetate.
PART - V : STUDIES ON THIAZOLIDINONES
It has been reported that 5-arylidene-4-thiazolidinone derivatives are
associated with wide range of biological activities like antitumor, antileprosy,
antitubercular, antibacterial etc. In order to develop medicinally important
compounds, we have synthesised some new arylidenes shown as under.
SECTION - I : Synthesis and biological evaluation of 2-Aryl
imino-3,N-aryl-5-[1',N-phenyl-3'-p-anisyl-4'-
pyrazolylmethino]-4-thiazolidinones
N
N
O
CH3
NH
O
R
N
Type (VII) R = Aryl
N
N
O
CH3
N
S
N
R
R
O
5
R = ArylType (VIII)
The arylidenes of type (VIII) have been prepared by condensation of
1,N-phenyl-3-p-anisyl-4-formyl-pyrazol with different thiazolidinones in
glacial acetic acid.
[B] STUDIES ON TRIAZOLES
We are engaged in a programme to explore some new heterocyclic
entities in order to study their pharmacological profile. Our efforts are focused
on introduction of chemical diversify in the molecular frame work in order
to synthesizing active molecule of widely different composition.
Compounds bearing 1,2,4-triazole moiety are endowed with a variety
of biological activities such as antiinflammatory, CNS depressant, herbicidal,
fungicidal etc.
Considering the increasing importance of triazole nucleus, it was
contemplated to synthesise some new aryl triazoles, azomethines, and
thiadiazoles bearing triazole nucleus, which have been described as under.
PART - I  : STUDIES ON 4-ARYLTRIAZOLES
Different type of 1,2,4-triazole derivatives have drawn considerable
attention due to their good pharmacological activities such as analgesic,
CNS depressent, pesticidal, antiinflammatory and antihypertensive. By
considering these valid observations, we have synthesised some new 1,2,4-
triazoles which have been described as under.
SECTION - I : Synthesis and biological evaluation of 3-
Mercapto-4,N-aryl-5-benzyl-1,2,4-triazoles
The synthesis of triazole derivatives of type (IX) have been undertaken
by heating of dithiocarbamate of phenyl acetic acid hydrazide with different
aromatic amines.
Type (IX) R = Aryl
N N
N
SH
R
6
PART - II  : STUDIES ON AZOMETHINES
Azomethine derivatives represent one of the modest classes of
compounds possessing wide range of therapeutic activities, such as
antimicrobial, antibacterial, antibiotics etc. With a view to getting better
therapeutic agents and to evaluate it's pharmacological profile, different type
of azomethine derivatives have been prepared, which have been described
as under.
SECTION - I : Synthesis and biological evaluation of 4-N-
Substituted benzalamino-3-benzyl-5-mercapto-
1,2,4-triazoles
The synthesis of schiff's base derivatives of type (X) have been prepared
by 3-mercapto-4-N-amino-5-benzyl-1,2,4-triazole with different aromatic
aldehydes in presence of sulphuric acid.
PART - III  : STUDIES ON 1,3,4-THIADIAZOLO TRIAZOLES
Thiadiazole derivatives represent one of the most active classes of
compounds possessing wide spectrum of biological activities such as
antithyroid, antibiotic,  pesticidal, antifungal etc. Some new triazoles with
1,3,4-thiadiazole ring system have been prepared as under.
N N
N
SH
N
R
Type (X) R = Aryl
7
SECTION - I : Synthesis and biological evaluation of 2-Aryl-4-
benzyl-1,2,4-triazolo[4,5-b]-1,3,4-thiadiazoles
Subst i tuted tr iazolo thiadiazoles (XI)  have been prepared by
condensation of 3-benzyl-4-N-amino-5-mercapto-1,2,4-triazole with
different aromatic acids in presence of phosphorous oxychloride.
SECTION - II : Synthesis and biological evaluation of 2-Aryl-4-
benzyl-2,3-dihydro-1,2,4-triazolo-[4,5-b]-1,3,4-
thiadiazoles
The compounds of type (XII) have been prepared by the condensation
of 3-benzyl-4-N-amino-5-mercapto-1,2,4-triazole with different aromatic
aldehydes in presence of p-toluenesulphonic acid.
The constitution of the newly synthesised products have been
characterised using elemental analyses, Infrared and 1H nuclear magnetic
resonance spectroscopy and further supported by mass spectrometry. Purity
of all the compounds have been checked by thin layer chromatography.
N N
N
S
N
R
Type (XI) R = Aryl
Type (XII) R = Aryl
N N
N
S
N
H R
8
In vitro study on multiple biological activites:
(i) All the compounds have been evaluated for their antibacterial activity
towards Gram positive and Gram nagative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of
40 µg/ml. The biological activity of the synthesised compounds have
been compared with standard drugs.
(ii) Selected compounds have been evaluated for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium
tuberculosis H37 Rv at a cocentration of 6.25 µg/ml using Rifampin
as a s tandard drug, which have been tested by Tuberculosis
Antimicrobial Acquisition Co-ordinating Facility (TAACF), Alabama
U.S.A. The work is under progress.
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DESIGN AND SYNTHESIS
OF SOME HETEROCYCLES
 OF MEDICINAL INTEREST
INTRODUCTION
With the advent of modern civilization, human learned to cure themself
by plant medicine. With the development of scientific knowledge, a more advance
form of drug have been evaluated. The continuous progress of drug design
ranging from single molecules to giant structure is extensively driven by the
insticts, intution and experience of pharmaceutical research scientists. From
ancient Aryuvedas people learn to use natural drugs as a curing tool. Thus
many natural products by trial and error come in to practice for combating
human ailments existant during early human observations. Such ancient plant
medicines are the 'base' for shaping our current drugs.
Taking in view of the applicability of heterocyclic compounds, they are
predominant among the types of compounds used as pharmaceuticals, as
agrochemicals, as veterinary products, as optical brightening agents, as
antioxidants, as corrosion inhibitors and as additives with a variety of other
function. Heterocyclic compounds are also finding an increasing use as
intermediates in organic synthesis. Heterocyclic compounds possess diversified
applicability in pharmaceuticals because they have specific chemical reactivity
and provides false synthon in biosynthetic process or block the normal
functioning of biological receptors.
Heterocyclic compounds are found as a key component in biological
processes. Nucleic acid bases, which are derivatives of the pyrimidine and purine
ring systems, as being crucial to the mechanism of replication. Heterocyclic
10
compounds like ascorbic acid (vitamin C) and thiamine (vitamin B1) are used
as an essential diet ingredients.
In ancient "Aryuvedas" NEEM has been described as a antifungal and
antibacterial medicine and till today it is being used against skin disease.
Moreover NEEM has described as killer for "Sarkara" (blood-sugar) and acts as
a antidiabetic drug in India. Similarly in China, Mauhang was in use for over
5000 years for the various types of fever & respiratory ailments.
In 1925 chemical investigations followed by pharmacological evaluation
led this compound into modern medicine. Similarly during this period, urea
stibamine was introduced as the first drug in 1920 for the treatment of Kala
azar, in 1930 De Roywolfia prepration were first employed for sedative and
hypotensive properties.
By serendipity, many such natural products have came into human
observations for the treatment & curing human illness. An extraordinary
chemotherapeutic properties of penicillin and it's dramatic time was developed
for the treatment of wound made penicillin, almost commonly used as an
inexpensive drug. The advent of sulphonamides draw attention to the different
activity of various chemicals for bacterial and human cells, this important factors
prompted the florey and chain in 1939 to investigate penicillins which was
discovered ten years earlier by Alexander Fleming.
A large number of important drugs have been introduced during this period
of 1940 to 1960. This period is known as 'Golden Period' of new drug discovery.
Thus prontosil leading various sulpha drugs ; 1940 - Penicillin, antibiotics ; 1945
- Chloroquine, an antimalarial; 1950 - Methyldopa, antihypertensive; 1957 -
chlorothiazide, diuretic; 1958 - adrenergic beta blockers, coronary vasodilatory;
1960 - semi synthetic penicillin, antibacterial; 1965 - trimethoprim, antimicrobial;
1967 - disodium chromoglycoate, antial lergic; 1972 - Cimetidine, H2 -
11
antagonis t ;  1975 -  Verapami l ,  Calc ium antagonis t ;  1981 -  captopr i l ,
ant ihyper tensive.  These are some speci f ic  examples represent ing new
therapeutics.
AIMS AND OBJECTIVES
With the consideration of the application of heterocyclic compounds, we
have carried out the preparation of heterocycles bearing pyrazole and triazole
nucleus. The placement of a wide variety of substituents of these nuclei have
been designed in order to evaluate the synthesised products for their
pharmacological profile against several strains of bacteria and fungi.
* To generate several derivatives like chalcones, isoxazoles, pyrazolines,
cyanopyridines, cyanopyridones, thiazolidinones bearing pyrazole moiety.
* To synthesise therapeutically active moieties like aryl triazoles, azomethines,
1,3,4-thiadiazoles bearing triazole nucleus.
* To characterise these products for structure elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
* Purity of all comopunds have been checked by thin layer chromatography.
* To evaluate these new products for better drug potential against different
strains of bacteria and fungi.
In a programmed research directed towards the construction of medicinally
active new heterocycles bearing pyrazole and triazole has been investigated in
following parts.
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A:
STUDIES ON
PYRAZOLES
INTRODUCTION
Pyrazoles, which belong to an important group of heterocyclic compounds,
have been extensively explored for their applications in the field of medicine,
agriculture and industrial chemistry.
SYNTHETIC ASPECTS
Different methods of preparation are available in literature which are as
under ;
1. By the reaction of ethylacetoacetate with aryl hydrazines1.
2. By the reaction of ethylacetoacetate with hydrazine hydrate2.
3. By the reaction of ethylacetoacetate with aroyl hydrazines3.
4. The ester group can be replaced by diazonium salt of amine and further it
is condensed with hydrazine which on cyclization form pyrazolone4.
CH3 O CH3
O O
N
NO
N
CH3
O
R1
NH
R
+ R NH2 R N N Cl
+
R1 NHNH2
O
R1, R = Aryl
13Pyrazoles...
THERAPEUTIC IMPORTANCE
Pyrazole derivatives have been reported to be associated with diverse
biological activities. Drug molecules having pyrazole nucleus with good
pharmacological activities are listed below.
14Pyrazoles...
N
N
NH
O
CH3
CH3
ON
CH3
CH3
N
N
O
(H2C)3CH3
O
OH
N
N
N
O
CH3
CH3
CH3
CH2SO3Na
N
N
NH
O
CH3
CH3
CH2SO3Na
Aminopropylon
(Antipyratic, Analgesic)
Oxyphenbutazone
(Antiarthritic)
Novalgin
(Antipyratic, Analgesic)
Melubrin
(Antipyratic, Analgesic)
N
N
CH3
CF3
S
O
O
NH2
Celecoxib
(Antiinflammatory)
Pyrazole derivatives exhibit broad spectrum of therapeutic activity. Several
biological activities associated with pyrazole derivatives have been described as
under.
1. Anticancer5
2. CNS depressant6
3. Antiulcer7
4. Herbicidal8,9
5. Antitumor10
6. Immunosuppresants11
7. Antimicrobial12
8. Antiparasitic13
9. Neurotonsin receptor14
10. Lipoxygenase inhibitor15
Ashok Kumar and co-workers16 have reported antibacterial activity of
pyrazolones. M. Giula et. al.17 have demonstrated pyrazolone derivatives as
antiinflammatory, analgesic and platelet, antiaggregating agent. S. D. Bharadwaj
and co-worker18 have observed anticancer and anti-HIV activity, associated
with some novel derivatives(I).
Barseiro et. al.19 have prepared pyrazole derivatives and reported them
as antiinflammatory and antiedematogenic agent (II).
15Pyrazoles...
N
N
N
N
CH3
O
O
R1
COOH
(I)
(II)
NN
Me
NO2
NH
N
R
Ph
El-Emery et. al.20 have synthesised 1,3-diphenyl pyrazole derivatives and
documented their variety of bioloical activity (III).
Rajeev Jain and co-worker21 have prepared pyrazoline derivatives and
reported as potent antimicrobial agent. X. X. Chun et. al.22 have prepared
substituted 3-methyl-5-pyrazoles (IV).
Havaldar Freddy et al.23 have synthesised 4,5-dihydro-3-phenyl-1H-
pyrazole and reported their biological activity. Carbau Romuald and co-
workers24 have reported pyrazole derivatives (V) useful as reverse transcriptase
inhibitors for the treatemet of HIV infection.
NN
Ph
CHO
Ph
(III)
(IV)
N
N
N
OH
N
O
N
O
Me
R
(V)
Cl
Cl
S
N
N
Me
Me
OH
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Recently, Atkinson R. N. et al.25 have studied pyrazoles as sodium channel
blocker (VI). Murakanii Hiroshi et al.26 have documented pyrazoles as antifouling
agents. Gellibeat Francoise et al.27 have reported purasole derivatives as TGF-
13 inhibitors.
Laborde Edgardo et al.28 have found that pyrazoles possess glycine
transporter2-inhibitors activity. Andrew Thurkaub et al.29 have synthesised high
affinity C5a receptor modulator pyrazoles. Nagaaki Sato et al.
30 have prepared
pyrazoles as neuropeptide T5 receptor antagonists. G. M. B. Yamanouch Pharma.
Co31 has suggested pyrazoles as glycine trnsporter protein inhibitors (VII).
Jacques Dumas and co-workers32 have shown pyrazole derivatives as
rafkinase and angiogenesis inhibitor agents. David L. S. et al.33 have synthesied
pyrazoles as activators of the nitrile oxide receptor and soluble guanglute cyclase
agent. T. Van Herk et al.34 have studied pyrazoles as nicotinic acid receptor
(VIII). Barber Christopher et al.35 have represented pyrazole derivatives as
phosphidiesterase inhibitors.
(VII)
N
N
CF3
Cl
O
NH N
(VI)
N
N
N
H
F
O
O
C2H5
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Nishimura Tsoshihiro et al.36 have synthesised pyrazole as inhibitors of
human SGLT2 (Sodium dependent glucose transporter-2).
Now a days, it is found that pyrazole derivatives possesses a number of
biological activities. Such as fungicidal37,38 ,herbicidal39,40,Cardiovascular41,
antiinflammatory42,43, anticancer44-46, antiviral47 and protein kinase
inhibitors48.
Loking to the diversified biological activity, it appeared of interest to
synthes ise some Chalcones,  I soxazoles ,  Pyrazol ines,  Cyanopyr id ines,
Cyanopyridones and Thiazolidinones bearing pyrazole moiety, in order to
achieving compounds having better therapeutic importance. These study are
described in following parts.
[A] STUDIES ON PYRAZOLES
PART-I : STUDIES ON ISOXAZOLES
PART-II : STUDIES ON PYRAZOLYLPYRAZOLINES
PART-III : STUDIES ON CYANOPYRIDINES
PART-IV : STUDIES ON CYANOPYRIDONES
PART-V : STUDIES ON THIAZOLIDINONES
N
N
H
R2
R1
O
OH
(VIII)
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PART - I
STUDIES ON
ISOXAZOLES
INTRODUCTION
Isoxazoles are a group of heterocyclic compounds containing two hetero
atoms : Oxygen and Nitrogen.
In 1888, Claisen first suggested an Isoxazole (I) for a product from the
reaction of 1,3-diketone with hydroxylamine49. Subsequently a solid foundation
for the chemistry of isoxazoles was laid down by Claisen and his students. It
was shown to possess typical properties of an aromatic system but under certain
reaction conditions, particularly in reducing or basic media, it becomes highly
labile. The next important contribution to the chemistry of isoxazole was made
by Quilico in 1946, when he began to study the formation of isoxazoles from
nitrile N-oxides and unsaturated compounds50.
SYNTHETIC ASPECTS
Isoxazoles may be prepared by the reaction between hydroxylamine and
α,β-dicarbonyl compounds. The reaction proceeds via the formation of an oxime,
which possibly undergoes cyclization.
(I)
N
O
R
O O
R'
NH2OH
O
N
R
H
R'
O
ON
R'
OH
R
ON
R'
R
-H2O
(II)
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Isoxazoles can be prepared by various methods which are described as
under.
1. Fanshawe and Crawley51 prepared isoxazoles (III) from chalcones,
hydroxylamine hydrochloride and KOH in methanol.
THERAPEUTIC IMPORTANCE
Isoxazoles possess wide therapeutic activities.
1. Antiinflammatory52-54
2. Anticonvulsant55,56
3. Muscle relaxant57,58
4. Antipyretic59
5. Anticholestermic60
6. Antibacterial61,62
7. Diabetic63
8. Nematocidal64
9. Antiviral65
10. Herbicidal66
11. Antileukemia67
12. Antitumor68
G. Daidone, Maggio et. al.69 synthesised novel 3-(isoxazol-3-yl)-quinazolin-
4(3H)-one derivatives and tested for their analgesic and antiinflammatory
activities as well as for their acute toxicity and ulcerogenic effect. Some of them
had a very low ulcerogenic effect.
+R'
O
R N
O
R
R'
NH2
OH
(III) R, R' = Aryl
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C. B. Xue et. al.70 reported that replacement of the benzamide in XUO57
(potent inhibitor) with an isoxazole carboxamide resulted in significant
improvement in vivo potency. More importantly, the analogue XUO65 showed
an excellent oral antiplatelet effect in dogs. Masui et. al.71 have prepared
isoxazoles having pesticidal activity. Some excellent herbicidal results are
obtained by Reddy et. al.72. Moreover isoxazoles found to possess remarkable
anxiolytic and antihypertesive effect, reported by Nyitrai et. al.73. Mishra et.
al.74 have synthesised and reported isoxazoles as useful agents for analgesic
and antiinflammatory activities. Aicher et. al.75 cited some isoxazole derivatives
possessing hypoglycemic agents.
R. Ulrich et. al.76 have synthesised isoxazole derivatives (IV) and reported
their adrenergic antagonist activity.
M. Dauria77 studied photochemical behaviour of isoxazole derivatives.
Manohara Y. N. et. al.78 investigated thermal decomposition kinetics of Co(II)
and Ni(II) complexes of substituted isoxazole and their antibacterial activity.
CONTRIBUTION FROM OUR LABORATORY
R. C. Khunt, A. R. Parikh and co-workers79 have prepared isoxazole
derivatives which possess antimicrobial activity. P. M. Patel and A. R. Parikh80
have synthesised 3-(3'-bromo-4-acetamidophenyl)-5-aryl-isoxazoles showing
antimicrobial activity. N. J. Datta et. al.81 have described the isoxazole
derivatives and their use as antimicrobial agents. B. P. Kansagara et. al.82 have
demonstrated various isoxazoles and tested their antimicrobial activity.
N
N
R2
R1R
NH
O
O
NH [CH2]n
R3
(IV)
Isoxazoles...
R=alkyl
R1,R2=H, halogen
R3= H, halo, alky1, alkoxy
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N. A. Vekariya, M. D. Khunt and co-workers83 have reported isoxazole
derivatives bearing quinoxaline moiety and described their anticancer activity.
Sushil Korgaokar et. al.84 have suggested 5-Aryl-3-(3'-ρ-chlorobenzene
sulphonamidophenyl)-isoxazole derivatives as antimicrobial. A. H. Bhatt and
co-workers85 have synthesised isoxazole derivatives and described them as
potential antimicrobial agents. Rajeev doshi et. al.86 have prepared some novel
isoxazole derivatives and reported as a new class of potential antitubercular
agents. Manish Shah and co-workers87 have demonstrated isoxazoles from 2-
hydroxy-3,4-dichloroacetophenone as potential antimicrobial agents.
Xin-Ping Hui et. al.88 have synthesised 1,3,4-oxadiazole derivatives (V)
containing 5-methylisoxazole moiety and reported their antibacterial activity.
Chaumin, Wang, Yunfeng et. al.89 have synthesised isoxazoles as herbicidal.
Archana et. al.90 have prepared isoxazoles as anticonvulsant agents. Wu,
Chengde et. al.91 have synthesised isoxazole derivatives as endothelin activity
modulators.  Corolin C. and co-workers92 have studied isoxazoles, which have
been used for the clinical trials of asthama.
With an intension of preparing the compounds possessing better therapeutic
activity, we have undertaken the preparation of isoxazoles bearing pyrazole
moiety which have been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-
ARYL-3-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-
2-PROPENE-1-ONES
SECTION - II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
ARYL-5-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-
ISOXAZOLES
Isoxazoles...
(V)
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O
N
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CH3
R1
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O
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-[1',N-
PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-2-PROPENE-1-ONES
Recently, much interest has been focused on the synthesis and biodynamic
activities of chalcones and it is a good synthon for various heterocycli rings.
With a view to obtain compounds having better therapeutic activity, we have
synthesised 1-aryl-3-[1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-yl]-2-propene-1-ones by
the condensation of 1-phenyl-3-ρ-anisyl-4-formyl pyrazole with various aromatic
ketones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. wehen R=p-bromophenyl, molecular
weight=459, m/z=461(m+2).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40
µg./ml. The biological activities of synthesised compounds were compared with
standard drugs.
N
N
O
R
O
CH3
Type (I) R = Aryl
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REACTION SCHEME
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O
CH3
R CH3
O
40% KOH
N
N
CHO
O
CH3
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CH3
CH3
Formylation by
Vilsmeir-Haack
Abs. C2H5OH
Cat. gla. acetic acid
O
CH3CH3
O
NH
NH2
+
Type (I) R = Aryl
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ANTIMICROBIAL ACTIVITY
Method : Cup-plate93
Gram Positive bacteria : Staphylococcus aureus
Bacillus megaterium
Gram negative bacterial : Proteus vulgaris
Escherichia coli
Fungi : Aspergillus niger
Concentration : 40µg
Solvent : Dimethyl formamide
Standard drugs : Ampicillin, Amoxicillin,
Norfloxacin, Penicillin, Greseofulvin.
The antimicrobial activity was compared with standard drug viz. Ampicillin,
Amoxicillin, Norfloxacin, Penicillin and antifungal activity was compared with
viz. Greseofulvin. The inhibition zones measured in mm.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-[1',N-
PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-2-PROPENE-1-ONES
(A) Synthesis of N-Aminophenyl-α-methyl-ρ-anisyl azomethine
A mix ture  o f  pheny lhydraz ine  (1 .08 g ,  0 .01 M)  and ρ -methoxy
acetophenone (1.50 g, 0.01 M) in absolute ethanol was refluxed in water bath
for 2 hrs. in presence of 1 ml glacial acetic acid. The crude product was isolated
and crystallised from absolute alcohol. Yield 90%, m.p. 38oC; (Anal. Found : C,
74.91; H, 6.69; N, 11.62%; C15H16N2O Requires: C, 74.97; H, 6.71; N,
11.66%).
(B) Synthesis of 1,N-Phenyl-3-ρ-anisyl-4-formyl pyrazole
N-Aminophenyl-α-methyl-ρ-anisyl azomethine (2.4 g, 0.01 M) was added
in mixture of Vilsmeier-Haack reagent (prepared dy dropwise addition of 3 ml
POCl3 in ice cooled 25 ml DMF) and refluxed for 5 hrs. The reaction mixture
was poured into ice followed by neutralization using sodium bicarbonate. Crude
product was isolated and crystallised from ethanol. Yield 75%, m.p. 164oC;
(Anal. Found : C, 73.33; H, 5.02; N, 10.01%; C17H14N2O2 Requires: C, 73.37;
H, 5.07; N, 10.07%).
(C) Synthesis of 1-(ρ-Bromophenyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl)-2-propene-1-one
To a well stirred solution of 1-N-phenyl-3-ρ-anisyl-4-formyl pyrazol (2.78
g, 0.01 M) and ρ-bromoacetophenone (2 g, 0.01 M) in ethanol (25 ml), 40%
KOH added till the solution was basic. The reaction mixture was stirred for 24
hrs. The contents were poured into ice, acidified, filtered and crystallised from
ethanol. Yield 74%, m.p. 170oC; (Anal. Found : C, 65.32; H, 4.68; N, 6.03%;
C25H19N2O2Br Requires: C, 65.37; H, 4.71; N, 6.10%).
Similarly other substituted pyrazolone have been prepared. The physical
data are recorded in Table No. 1.
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(D) Antimicrobial activity of 1-Aryl-3-[1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl]-2-propene-1-ones
All the products have been evaluated by antimicrobial activity as described
under.
(a) Antimicrobial activity
It was carried out by cup-plate diffusion method which has been described
as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by the usual method, was inoculated aseptically
with 0.5 ml of 24 hrs. old subcultures of B. megaterium, S. aureus, E. coli,
P. vulgaris in separate conical flask at 40-50oC and mixed well by gentle shaking.
About 25 ml content of the flask were poured and evenly spreaded in a petridish
(13 cm in diameter) and allowed to set for 2 hrs. The cups (10 mm in diameter)
were formed by the help of borar in agar medium and filled with 0.04 ml
(40 µg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 ml of DMF in a similar manner and the zones of inhibition
of the bacterial growth were measured in millimeter and are recorded in graphical
Chart No. 1.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using Cup-plate
method. The culture was maintained on Sabouraud's agar slants. Sterillised
Sabouraud's agar medium was inoculated with 72 hrs. old 0.5 ml of suspension
of fungal spores in a separate flask. About 25 ml of the inculated medium was
evenly spreaded in a petridish and allowed to set for two hrs. The cups (10 mm
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in diameter) were punched. The plates were incubated at 30oC for 48 hrs. After
the completion of incubation period, the zones of inhibition of growth in the
form of diameter in mm was measured. Along the test solution, in each petridish
one cup was filled up with solvent which acts as control. The zones of inhibition
are recorded in Graphical Chart No. 1.
(b) Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordinating Facility (TAACF),
U.S.A. Primary screening of the compounds for antitubercular activity have been
conducted at 6.25 µg/ml towards Mycobacterium Tuberculosis H37Rv in
BACTEC 12B medium using the BACTEC 460 rediometric system. The
compounds demonstrating atleast >90% inhibition in the primary screen have
been retested at lower concentration towards Mycobacterium Tuberculosis
H37Rv to determine the actual minimum inhibitory concentration (MIC) in the
BACTEC 460.
The antitubercular activity data have been compared with standard drug
Rifampin at 0.25 µg/ml concentration and it showed 98% inhibition. The work
is under progress.
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IR SPECTRAL STUDY OF 1-(ρ-BROMOPHENYL)-3-(1',N-PHENYL-3'-ρ-ANISYL-
PYRAZOL-4'-YL)-2-PROPENE-1-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str.(asym.) 2972.1 2975-2950 434
-CH3 C-H str. (sym.) 2879.5 2880-2860 "
C-H def. (asym.) 1438.8 1470-1435 "
C-H def. (sym.) 1361.7 1385-1350 "
Aromatic C-H str. 3070.5 3080-3030 435
C=C str. 1502.4 1585-1480 "
C-H i.p. def. 1109.0 1125-1090 "
1066.6 1070-1000 "
C-H o.o.p. def. 825.5 835-810 "
Pyrazole C=N str 1502.4 1650-1600 434
moiety C-N str. 1249.8 1350-1200 "
C-Br 600-500 "
Ether C-O-C str. (asym.) 1213.1 1275-1200 "
C-O-C str. (sym.) 1026.1 1075-1020 "
Chalcone C=O str. 1654.8 1760-1655 "
CH=CH 2999.1 3050-3000 "
N
N
O
O
CH3
Br
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PMR SPECTRAL STUDY OF 1-(ρ-BROMOPHENYL)-3-(1',N-PHENYL-3'-ρ-ANISYL-
PYRAZOL-4'-YL)-2-PROPENE-1-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.88 3H singlet Ar-OCH3
2 7.03 Jgf=8.7 2H doublet Ar-Hgg'
3 7.34 2H quartret Ar-Hc, Ar-He
4 7.44 Jhi=8.7 2H doublet Ar-Hhh'
5 7.46-7.50 Jzy=12.0 1H doublet CHz(vinylic)
6 7.51 1H doublet Ar-Hd
7 7.63 Jfg=8.7 2H doublet Ar-Hff'
8 7.79 Jih=8.7 2H doublet Ar-Hii'
9 7.87-7.92 2H multiplet Ar-Ha, Ar-Hb
10 7.88-7.92 Jyz=12.0 1H doublet CHy (vinylic)
11 8.34 1H singlet CHx
N
N
O
O
CH3
Br
ae
d
c b x y
z
i'
h'
i
h
f
g
f'
g'
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1a C6H5- 1656
1b 4-NH2-C6H4- 1658
1c 3-NH2-C6H4- 1662
1d 4-Br-C6H4- 1654.8
1e 4-Cl-C6H4- 1658.7
1g 4-F-C6H4- 1654
1h 4-OCH3-C6H4- 1656
1i 4-CH3-C6H4- 1666.4
1j 4-NO2-C6H4- 1658
1m 3-NO2-C6H4- 1662
1n 4-OH-C6H4- 1666
1o 2-OH-C6H4- 1660
Sr.
 No. R
C=O str.
Chalcones
EXPANDED AROMATIC REGION
IR SPECTRAL DATA OF 1-ARYL-3-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-2-
PROPENE-1-ONES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
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TABLE NO. 1 : PHYSICAL CONSTANTS OF 1-ARYL-3-(1',N-PHENYL-3'-ρ -ANISYL-PYRAZOL-4'-YL)-2-
PROPENE-1-ONES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
1a C6H5- C25H20N2O2 380 190 0.42 82 7.36 7.32
1b 4-NH2-C6H4- C25H21N3O2 395 209 0.58 83 10.63 10.58
1c 3-NH2-C6H4- C25H21N3O2 395 214 0.48 71 10.36 10.56
1d 4-Br-C6H4- C25H19N2O2Br 459 170 0.51 74 6.10 6.03
1e 4-Cl-C6H4- C25H19N2O2Cl 415 152 0.62 87 6.75 6.71
1f 4-F-C6H4- C25H19N2O2F 398 169 0.72 85 4.77 4.70
1g 4-OCH3-C6H4- C26H22N2O3 410 186 0.45 75 6.82 6.78
1h 4-CH3-C6H4- C26H22N2O2 394 158 0.55 83 7.10 7.05
1i 4-NO2-C6H4- C25H19N3O4 425 161 0.65 71 9.88 9.82
1j 3-NO2-C6H4- C25H19N3O4 425 181 0.56 78 9.88 9.81
1k 4-OH-C6H4- C25H20N2O3 396 179 0.72 82 7.07 7.04
1l 2-OH-C6H4- C25H20N2O3 396 166 0.57 78 7.07 7.01
*TLC Solvent System : Ethylacetate : Hexane 2 : 8 (1a-1l)
3 :7 (1b, 1i)
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1',N-
PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-ISOXAZOLES
With a view to achieving better drug potency, isoxazole derivatives of type
(II) have been prepared by the condensation of chalcones of type (I) with
hydroxylamine hydrochloride in presence of sodium acetate in glacial acetic
acid. The chalcones were synthesised by the condensation of 1,N-phenyl-3-ρ-
anisyl-4-formyl pyrazole with different aromatic ketones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i .e. when R=p-bromophenyl, molecular
weight=472,            m/z=473 (m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
N
N
O
CH3
NO
R
R = ArylType (II)
NH2OH.HCl
CH3COONa
N
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1',N-
PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-ISOXAZOLES
(A) Synthesis of N-Aminophenyl-α-methyl-ρ-anisyl azomethine
See Part - I, Section - I(A).
(B) Synthesis of 1,N-Phenyl-3-ρ-anisyl-4-formyl pyrazole
See Part - I, Section - I(B).
(C) Synthesis of 1-(ρ-Bromophenyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl)-2-propene-1-one
See Part - I, Section - I(C).
(D) Synthesis of 3-(ρ-Bromophenyl)-5-(1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl)-isoxazole
To a mixture of hydroxylamine hydrochloride (0.79, 0.01 M) in ethanol
and anhydrous sodium acetate (0.82 g, 0.01 M) dissolved in minimum amount
of hot acetic acid was added a solution of 1-(ρ-bromophenyl)-3-(1',N-phenyl)-
3'-ρ-anisyl-pyrazol-4'-yl)-2-propene-1-one (4.59, 0.01 M) in ethanol (15 ml). The
contents were refluxed on waterbath for 8 hrs. The reaction product was poured
into ice and crystallised from ethanol. Yield 73%, m.p. 140oC; (Anal. Found : C,
63.52; H, 3.80; N, 8.86%; C25H18N3O2Br Requires: C, 63.57; H, 3.84; N,
8.90%).
Similarly other substituted isoxazoles have been prepared. The physical
data are recorded in Table No. 2
(E) Antimicrobial activity of 3-Aryl-5-[1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl]-isoxazoles
Antimicrobial testing was carried out as described in Part - I, Section - I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 2
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IR SPECTRAL STUDY OF 3-(ρ-BROMOPHENYL)-5-(1',N-PHENYL-3'-ρ-ANISYL-
PYRAZOL-4'-YL)-ISOXAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str.(asym.) 2960.5 2975-2950 434
-CH3 C-H str. (sym.) 2866.0 2880-2860 "
C-H def. (asym.) 1436.9 1470-1435 "
C-H def. (sym.) 1357.8 1385-1350 "
Aromatic C-H str. 3030.0 3080-3030 435
C=C str. 1496.7 1585-1480 "
C-H i.p. def. 1128.3 1125-1090 "
1066.6 1070-1000 "
C-H o.o.p. def. 821.6 835-810 "
Pyrazole C=N str. 1612.4 1650-1600 434
moiety C-N str. 1245.9 1350-1200 "
C-Br str. 505.0 600-500 "
Ether C-O-C str. (asym.) 1220.9 1275-1200 "
C-O-C str. (sym.) 1020.3 1075-1020 "
Isoxazole C=C str. 1581.5 1585-1570 "
C=N str. 1460.0 1470-1460 "
N-O str. 839.0 850-800 "
N
N
O
CH3
NO
Br
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PMR SPECTRAL STUDY OF 3-(ρ-BROMOPHEYL)-5-(1',N-PHENYL-3'-ρ-ANISYL-
PYRAZOL-4'-YL)-ISOXAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.87 3H singlet Ar-OCH3
2 7.23 Jgf=8.7 2H doublet Ar-Hgg'
3 7.34 2H triplet Ar-Hc, Ar-He
4 7.44 Jhi=8.7 2H doublet Ar-Hhh'
5 7.50 2H doublet Ar-Hd, CHy(isoxazole)
6 7.63 Jfg=8.7 2H doublet Ar-Hff'
7 7.78 Jih=8.7 2H doublet Ar-Hii'
8 7.86-7.92 2H multiplet Ar-Ha, Ar-Hb
9 8.34 1H singlet CHx
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EXPANDED AROMATIC REGION
N
N
O
CH3
NO
Br
m/z = 473 (m+1)
40
Comp.
No.
1
TABLE NO. 2 : PHYSICAL CONSTANTS OF 3-ARYL-5-(1 ' ,N-PHENYL-3' -ρ -ANISYL-PYRAZOL-4' -YL)-
ISOXAZOLE
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
2a C6H5- C25H19N3O2 393 155 0.61 69 10.68 10.62
2b 4-NH2-C6H4- C25H20N4O2 408 178 0.57 70 13.72 13.69
2c 3-NH2-C6H4- C25H20N4O2 408 162 0.60 72 13.72 13.65
2d 4-Br-C6H4- C25H18N3O2Br 472 140 0.56 73 8.90 8.86
2e 4-Cl-C6H4- C25H18N3O2Cl 426.5 156 0.55 75 9.82 9.77
2f 4-F-C6H4- C25H18N3O2F 411 188 0.48 62 10.21 10.15
2g 4-OCH3-C6H4- C26H21N3O3 423 159 0.69 75 9.92 9.89
2h 4-CH3-C6H4- C26H21N3O2 407 148 0.72 68 10.31 10.28
2i 4-NO2-C6H4- C25H18N4O4 438 210 0.47 71 12.78 12.71
2j 3-NO2-C6H4- C25H18N4O4 438 181 0.60 64 12.78 12.73
2k 4-OH-C6H4- C25H19N3O3 409 165 0.75 71 10.26 10.22
2l 2-OH-C6H4- C25H19N3O3 409 146 0.45 64 10.26 10.20
*TLC Solvent System : Ethylacetate : Hexane (3 : 7)
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PART - II
STUDIES ON
PYRAZOLYL
PYRAZOLINES
INTRODUCTION
A pharmacological study of nitrogen containing five membered heterocyle,
pyrazolines have proved them to be the most important molecule for the
pharmacists. A dual feature l ike heterocylic & pharmacologically active
pyrazolines attracted attention of medicinal chemists for their biological evalution
as a drug. In 1967 Jarobe, reviewed the chemistry of pyrazolines, which have
been studied extensively for their biodynamic behaviour94 and industrial
applications95.
SYNTHETIC ASPECTS
Dif ferent  method for  the preparat ion of  2-pyrazol ine der ivat ives
documented in literature are as follows.
1. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones
with hydrazine hydrate96.
2. 2-Pyrazolines can also be prepared by the condensation of chalcone
dibromide with hydrazines97.
3. 2-Pyrazolines can be synthesised by the cycloaddition of diazomethane to
substituted chalcones98.
N
H
N
N
H
NR
R1
R
O
R1
+ NH2.NH2.H2O
Pyrazolyl pyrazolines...
R
1
, R = Aryl
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4. Dipolar cycloaddition of nitrilimines of dimethyl fumerate, fumaronitrile
and the N-aryl maleimides yields the corresponding pyrazolines99.
5. Epoxidation of chalcones have epoxy ketones which reacted with hydrazine
and phenyl hydrazine to give pyrazoline100.
REACTION MECHANISM
The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate101.
Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated
carbonyl system forms species (II), in which the -ve charge is mainly accomodated
by the electronegative oxygen atom. Proton transfer from the nitrogen to -ve
oxygen produces an intermediate enol which simultaneously ketonises to
ketoamine (III). Another intermolecular nucleophilic attack by the primary amino
group of ketoamine on its carbonyl carbon followed by proton transfer from
nitrogen to oxygen leads ultimately to carbonyl amine (IV). The later with a
hydroxy group and amino group on the same carbon lose water easily to yield
the pyrazolines (V).
::
Pyrazolyl pyrazolines...
R1R
O
NH2-NH
O-
C+
CH- RR1
NH
R2 NH2
( i ) proton transfer
( ii ) ketonisation
O
RR1
N
NH2R2
nucleophillic attack
intermolecular
N N
H
OH
RR1
R2
-H2O
N N
RR1
R2
R2
(II)(I) (III)
(IV)(V)
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THERAPEUTIC IMPORTANCE
From the literature survey, it was revealed that 2-pyrazoline derivatives
shows following activities.
1. Analgesic102
2. Bactericidal103
3. Cardiovascular104
4. Diuretic105
5. Fungicidal106
6. Herbicidal107
7. Hypoglycemic108
8. Insecticidal109
9. Tranquilizing110
10. Antiallergic111
11. Anticonvulsant112
12. Antidiabetic113
13. Antiimplantation114
14. Antiinflammatory115
15. Antitumor116
16. Antineoplastic117
F. Manna and co-workers118 have described 1-acetyl-5-(2'-bromophenyl)-
4,5-dihydro-3-(2'-hydroxyphenyl)-1H-pyrazoline (I) and its derivatives which acts
as potent antiinflammatory, analgesic and antipyretic agents.
NN
OH
N
H3COC
R
R1
CH3
CH3
(I)
Pyrazolyl pyrazolines...
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Nugent Richard119 investigated pyrazolines bis phosphonate ester as novel
antiinflammatory and antiarthritic agents. Furthermore, Tsuboi et. al.120 have
synthesised some new (phenylcarbonyl) pyrazoline (II) as an insecticides and at
40% concentration shows 100% mortality of spodopetra litura larve after seven drops.
Tuntaway, Atif and co-workers121 have patented 3-methyl-4'-(substituted
phenylazo)-pyrazol-5-ones as antibacterial agents. Fuche Rainer et. al.122 have
prepared some 1H-pyrazoline (III) derivatives and reported them as pesticides.
Johannes et. al.123 have patented pyrazoline derivatives as insecticides. S. S.
Sonarc et .  a l .124 have synthesised 3-(2-acetoxy-4-methoxyphenyl)-5-
(substitutedphenyl)-pyrazolines (IV) and tested their antimicrobial activity.
G. N. Mishirika et. al.125 have also prepared 2-Pyrazoline derivatives of
salicyclic acid (V) possessing antimicrobial properties.
Pyrazolyl pyrazolines...
N
N
O
NH
CF3
R (II) R = Aryl
NN
OACH3CO
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(III) (IV) R, R1, R2 = Aryl
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Udupi R. H. and Bhat A. R.126 have reported the synthesis and biological
activity of Mannich bases of certain 1,2-pyrazolines. Moreover, T. M. Stivenson
et. al.127 have also investigated N-Substituted pyrazoline type insecticide. Tanka
Katsushori128 et. al. have patented pyrazoline derivatives as herbicides. Moritaz
Z. and Hadol129 have demonstrated a semi emperial molecular orbital study
on the reaction of amino-pyrazolinyl azo dye with singlet molecular oxygen.
Shivananda M. K. and co-workers130 have prepared pyrazolines and reported
their antibacterial activity.
CONTRIBUTION FROM OUR LABORATORY
Parekh et. al.131 have prepared 1-acetyl-5-aryl-3-[3-(3,4-dihydro-2-methyl-
4-one-3-quinazolinyl)-phenyl]-2-pyrazolines which possess antimicrobial activity.
Several pyrazolines bearing thymol moiety were evaluated for their ability as
potent antimicrobial by K. P. Roda132. Vikani and co-workers133 have prepared
pyrazoline derivatives from arsanilic acid for their antimicrobial activity. Parekh
et. al.134 have synthesised and reported the antimicrobial activity of pyrazoline
derivatives.
Jatin Upadhyay et. al.135 have described by the pyrazoline derivatives
and their use as antimicrobial agents. Akhil Bhatt and co-workers136 have
reported pyrazoline derivatives showing antimicrobial activity. Parekh et. al.137
have synthesised phenyl pyrazoline derivatives bearing quinoline (VI) moiety
and described their antimicrobial activity.
(V)
NN
R
R
OH
COOH
Pyrazolyl pyrazolines...
R = Aryl
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E. Palska et. al.138 have prepared 3,5-diphenyl-2-pyrazoline derivatives
(VII) and studied their antidepressant activity. B. Shivarama Holla et. al.139
have prepared some fluorine containing pyrazolines and N-acetyl pyrazolines
as  antibacterial agents. Guinizkucukguzel et. al.140 have synthesised pyrazolines
(VIII) as antimicrobial and anticonvulsant agents.
Gulhan Taran-Zitouni et. al.141 have demonstrated 1-(4-arylthiazol-2-yl)-
3,5-diaryl-2-pyrazolines (IX) as antihypertensive agents. S. P Hiremath et. al.142
have reported substituted pyrazolines as analgesic, antiinflammatory and
antimicrobial agents. Malhotra et. al.143 have prepared   1-thiocarbamoyl-2-
pyrazolines derivatives (X) as anticardiovascular agents.
(VI)
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Archana and V. K. Shrivastava et. al.144 have synthesised quinazolinoyl
pyrazoline  as anticonvulsant agents. Almastead et. al.145 have reported
pyrazoline derivatives to increase erythropdietin and vascularization.
With an aim to synthesise better therapeutic agents, we have investigated
some new pyrazolines, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
ARYL-5-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-
PYRAZOLINES
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1,N-ACETYL-3-ARYL-5-[1',N-PHENYL-3'-ρ-ANISYL-
PYRAZOL-4'-YL]-PYRAZOLINES
SECTION-III : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1,N-PHENYL-3-ARYL-5-[1',N-PHENYL-3'-ρ-ANISYL-
PYRAZOL-4'-YL]-PYRAZOLINES
Pyrazolyl pyrazolines...
N N S
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1',N-
PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-PYRAZOLINES
Pyrazoline derivatives are endowed with valid antimicrobial activities.
Looking at their versatile therapeutic importance and with an aim to getting
better drug, it was considered worthwhile to synthesise some new pyrazolines.
The preparation of 3-Aryl-5-(1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-yl) pyrazolines
(III) has been undertaken by cyclocondensation of chalcones of type (II) with
hydrazine hydrate.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i .e. when R=p-chlorophenyl, molecular
weight=429,   m/z=430 (m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
R = ArylType (III)
N
N
O
R
O
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NH2NH2H2O
N
N
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R
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1',N-
PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-PYRAZOLINES
(A) Synthesis of N-Aminophenyl-α-methyl-ρ-anisyl azomethine
See Part - I, Section - I(A).
(B) Synthesis of 1,N-Phenyl-3-ρ-anisyl-4-formyl pyrazole
See Part - I, Section - I(B).
(C) Synthesis of 1-(ρ-Tolyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-yl)-2-
propene-1-one
See Part - I, Section - I(C).
(D) Synthesis of 3-(ρ-Tolyl)-5-(1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-yl)-
pyrazoline
A mixture of 1-(ρ-tolyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-yl)-2-propene-
1-one (3.94 g, 0.01 M) in 25 ml of absolute alcohol, add hydrazine hydrate (0.5
g, 0.01 M) was refluxed for 8 hrs. The reaction mixture was poured into ice. The
product was isolated and crystallised from ethanol. Yield 62%, m.p. 181oC;
(Anal. Found : C, 69.94 H, 4.87; N, 13.68%; C26H24N4O Requires: C, 70.01;
H, 4.93; N, 13.72%).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 3
(E) Antimicrobial activity of 3-Aryl-5-[1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl]-pyrazolines
Antimicrobial testing was carried out as described in Part - I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 3
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IR SPECTRAL STUDY OF 3-(ρ-TOLYL)-5-(1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-
YL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str.(asym.) 2956.7 2975-2950 434
-CH3 C-H str. (sym.) 2860.2 2880-2860 "
C-H def. (asym.) 1458.1 1470-1435 "
C-H def. (sym.) 1384.9 1385-1350 "
Aromatic C-H str. 3078.2 3080-3030 435
C-H i.p. def. 1105.1 1125-1090 "
1066.6 1070-1000 "
C-H o.o.p. def. 812.0 835-810 "
Pyrazole C=N str. 1598.9 1650-1600 434
moiety C=C str. 1502.4 1585-1480 "
C-N str. 1292.2 1350-1200 "
Ether C-O-C (asym.) 1249.8 1275-1200 "
C-O-C (sym.) 1028.0 1075-1020 "
Pyrazoline C=N str. 1614.3 1627-1580 437
C-H def. 690.5 698-690 "
N-H str. 3413.8 3450-3250 434
N-H def. 1598.0 1650-1580 "
(overlapped)
N
N
O
CH3
NNH
CH3
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PMR SPECTRAL STUDY OF 3-(ρ-TOLYL)-5-(1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-
YL)-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 2.44 3H singlet Ar-CH3
2 3.04 Jlk=17.4, Jlj=4.4 1H d. doublet CHl
3 3.57 Jkl=17.4, Jkj=11.6 1H d. doublet CHk
4 3.80 3H singlet Ar-OCH3
5 5.86 Jjk=11.6, Jjl=4.4 1H d. doublet CHj
6 6.92 Jgf=8.7 2H doublet Ar-Hgg'
7 7.26 1H triplet Ar-Hd
8 7.40 2H triplet Ar-Hc, Ar-He
9 7.48-7.54 4H multiplet Ar-Hhh'
Ar-Ha, Ar-Hb
10 7.64 Jih=8.7 2H doublet Ar-Hii'
11 7.67 Jfg=8.7 2H doublet Ar-Hff'
12 7.77 1H singlet CHx
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TABLE NO. 3 : PHYSICAL CONSTANTS OF 3-ARYL-5-(1 ' ,N-PHENYL-3' -ρ -ANISYL-PYRAZOL-4' -YL)-
PYRAZOLINES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
3a C6H5- C25H22N4O 394 131 0.52 58 14.20 14.15
3b 4-NH2-C6H4- C25H23N5O 409 159 0.42 61 17.10 17.06
3c 3-NH2-C6H4- C25H23N5O 409 170 0.37 65 17.10 17.04
3d 4-Br-C6H4- C25H21N4OBr 473 144 0.43 64 11.84 11.78
3e 4-Cl-C6H4- C25H21N4OCl 429 155 0.50 66 13.06 13.01
3f 4-F-C6H4- C25H21N4OF 412 141 0.61 62 13.58 13.54
3g 4-OCH3-C6H4- C26H24N4O2 424 164 0.74 60 13.20 13.17
3h 4-CH3-C6H4- C26H24N4O 408 181 0.66 62 13.72 13.68
3i 4-NO2-C6H4- C25H21N5O3 439 149 0.48 70 15.94 15.90
3j 3-NO2-C6H4- C25H21N5O3 439 160 0.34 72 15.94 15.89
3k 4-OH-C6H4- C25H22N4O2 410 178 0.39 64 13.65 13.62
3l 2-OH-C6H4- C25H22N4O2 410 165 0.51 68 13.65 13.59
*TLC Solvent System : Ethylacetate : Hexane (2 : 8)
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-
5-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-PYRAZOLINES
Looking to the interesting properties of pyrazolines, it was considered
worthwhile to synthesise a series of pyrazolines of type (IV) for obtaining
biologically potent agents which were prepared by reacting chalcones with
hydrazine hydrate in glacial acetic acid.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. wehen R=p-bromophenyl, molecular
weight=516, m/z=517(m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
N
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R
O
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gl. CH3COOH
R = ArylType (IV)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-
5-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-PYRAZOLINES
(A) Synthesis of N-Aminophenyl-α-methyl-ρ-anisyl azomethine
See Part - I, Section - I(A).
(B) Synthesis of 1,N-Phenyl-3-ρ-anisyl-4-formyl pyrazole
See Part - I, Section - I(B).
(C) Synthesis of 1-(ρ-Bromophenyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl)-2-propene-1-one
See Part - I, Section - I(C).
(D) Synthesis of 1,N-Acetyl-3-(ρ-bromophenyl)-5-(1'-N-phenyl-3'-ρ-
anisyl-pyrazol-4'-yl)-pyrazoline
To a mixture of 1-(ρ-bromophenyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-
yl)-2-propene-1-one (4.59 g, 0.01 M) in 25 ml of absolute alcohol, add hydrazine
hydrate (0.5 g, 0.01 M) and glacial acetic acid 10 ml added, the contents were
refluxed for 10 hrs., and poured into ice. The product was isolated and
crystallised from ethanol. Yield 70%, m.p. 180oC; (Anal. Found : C, 62.88 H,
4.45; N, 10.83%; C27H23N4O2Br Requires: C, 62.92; H, 4.50; N, 10.81%).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 4
(E) Antimicrobial activity of 1,N-Acetyl-3-aryl-5-[1',N-phenyl-3'-ρ-
anisyl-pyrazol-4'-yl]-pyrazolines
Antimicrobial testing was carried out as described in Part - I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 4
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IR SPECTRAL STUDY OF 1,N-ACETYL-3-(ρ-BROMOPHENYL)-5-(1',N-PHENYL-3'-
ρ-ANISYL-PYRAZOL-4'-YL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2970.1 2975-2950 434
-CH3 C-H str. (sym.) 2860.2 2880-2860 "
C-H def. (asym.) 1452.3 1470-1435 "
C-H def. (sym.) 1357.8 1385-1350 "
Aromatic C-H str. 3057.0 3080-3030 435
C-H i.p. def. 1108.9 1125-1090 "
1064.6 1070-1000 "
C-H o.o.p. def. 823.5 835-810 "
Pyrazole C=N str. 1612.4 1650-1600 434
moiety C=C str. 1504.4 1585-1480 "
C-N str. 1253.6 1350-1200 "
C-Br str. 536.2 600-550 "
Ether C-O-C (asym.) 1228.6 1275-1200 "
C-O-C (sym.) 1026.1 1075-1020 "
Pyrazoline C=N str. 1593.7 1627-1580 437
C-H def. 694.5 698-690 "
C=O 1651.0 1760-1655 434
N
N
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PMR SPECTRAL STUDY OF 1,N-ACETYL-3-(ρ-BROMOPHENYL)-5-(1',N-PHENYL-3'-
ρ-ANISYL-PYRAZOL-4'-YL)-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 2.43 3H singlet -COCH3
2 3.05 Jlk=13.0, Jlj=3.4 1H d. doublet CHl
3 3.55 Jkl=13.0, Jkj=8.7 1H d. doublet CHk
4 3.80 3H singlet Ar-OCH3
5 5.85 Jjk=8.7, Jjl=3.4 1H d. doublet CHj
6 6.93 Jgf=6.6 2H doublet Ar-Hgg'
7 7.07 2H triplet Ar-Hc, Ar-He
8 7.25 1H triplet Ar-Hd
9 7.41 2H triplet Ar-Ha, Ar-Hb
10 7.61-7.68 6H multiplet Ar-Hhh'
Ar-Hii'
Ar-Hff'
11 7.77 1H singlet CHx
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4a C6H5- 1660
4b 4-NH2-C6H4- 1654
4c 3-NH2-C6H4- 1662
4d 4-Br-C6H4- 1651
4e 4-Cl-C6H4- 1658.7
4g 4-F-C6H4- 1666
4h 4-OCH3-C6H4- 1650
4i 4-CH3-C6H4- 1656.8
4j 4-NO2-C6H4- 1654
4m 3-NO2-C6H4- 1660
4n 4-OH-C6H4- 1655
4o 2-OH-C6H4- 1654
Sr.
 No. R
C=O str.
Acetylpyrazolines
IR SPECTRAL DATA OF 1,N-ACETYL-3-ARYL-5-[1' ,N-PHENYL-3'-ρ -ANISYL-
PYRAZOL-4'-YL]-PYRAZOLINES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
N
N
O
CH3
NN
CH3
O
Br
m/z = 517 (m+1)
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No.
1
TABLE NO. 4 : PHYSICAL CONSTANTS OF 1,N-ACETYL-3-ARYL-5-(1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-
4'-YL)-PYRAZOLINES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
4a C6H5- C27H24N4O2 436.5 220 0.48 73 12.84 12.79
4b 4-NH2-C6H4- C27H25N5O2 451.5 212 0.55 60 15.51 15.47
4c 3-NH2-C6H4- C27H25N5O2 451.5 185 0.39 65 15.51 15.49
4d 4-Br-C6H4- C27H23N4O2Br 516 180 0.46 70 10.87 10.81
4e 4-Cl-C6H4- C27H23N4O2Cl 471 155 0.74 71 11.90 11.86
4f 4-F-C6H4- C27H23N4O2F 454 178 0.51 66 12.33 12.28
4g 4-OCH3-C6H4- C28H26N4O3 466.5 175 0.61 71 12.01 11.96
4h 4-CH3-C6H4- C28H26N4O2 450.5 202 0.66 64 12.44 12.40
4i 4-NO2-C6H4- C27H23N5O4 481.5 181 0.47 75 14.54 14.49
4j 3-NO2-C6H4- C27H23N5O4 481.5 190 0.78 62 14.54 14.51
4k 4-OH-C6H4- C27H24N4O3 452.5 179 0.42 68 12.38 12.35
4l 2-OH-C6H4- C27H24N4O3 452.5 168 0.58 64 12.38 12.32
*TLC Solvent System : Ethylacetate : Hexane (2 : 8)
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SECTION - III
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-
ARYL-5-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-PYRAZOLINES
Looking to the interesting therapeutic activities of pyrazolines, it was
considered worthwhile to synthesise compounds bearing 1,N-phenyl-3-ρ-anisyl-
4-formyl pyrazole moiety linked to the pyrazoline of type (V) which have been
prepared by the action of 1-aryl-3-(1',N-phenyl-3-ρ-anisyl-pyazol-4'-yl)-2-
propene-1-ones with phenyl hydrazine in presence of piperidine.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. wehen R=p-bromophenyl, molecular
weight=549, m/z=550 (m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-
ARYL-5-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-PYRAZOLINES
(A) Synthesis of N-Aminophenyl-α-methyl-ρ-anisyl azomethine
See Part - I, Section - I(A).
(B) Synthesis of 1,N-Phenyl-3-ρ-anisyl-4-formyl pyrazole
See Part - I, Section - I(B).
(C) Synthesis of 1-(ρ-Bromophenyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl)-2-propene-1-one
See Part - I, Section - I(C).
(D) Synthesis of 1,N-Phenyl-3-(ρ-bromophenyl)-5-(1'-N-phenyl-3'-ρ-
anisyl-pyrazol-4'-yl)-pyrazoline
To a mixture of 1-(ρ-bromophenyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-
yl)-2-propene-1-one (4.59 g, 0.01 M) in 25 ml of absolute alcohol, add phenyl
hydrazine (1.08 g, 0.01 M) was added in presence of basic catalyst like piperidine
and refluxed for 12 hrs. The reaction product was poured into ice. The product
was isolated and crystallised from ethanol. Yield 68%, m.p. 160oC. (Anal. Found
: C, 67.71 H, 4.53; N, 10.16%; C31H25N4OBr Requires: C, 67.76; H, 4.59; N,
10.20%).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No.5
(E) Antimicrobial activity of 1,N-Phenyl-3-Aryl-5-[1',N-phenyl-3'-ρ-
anisyl-pyrazol-4'-yl]-pyrazolines
Antimicrobial testing was carried out as described in Part - I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.5
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IR SPECTRAL STUDY OF 1,N-PHENYL-3-(ρ-BROMOPHENYL)-5-(1',N-PHENYL-3'-
ρ-ANISYL-PYRAZOL-4'-YL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2958.6 2975-2950 434
-CH3 C-H str. (sym.) 2860.2 2880-2860 "
C-H def. (asym.) 1452.3 1470-1435 "
C-H def. (sym.) 1384.8 1385-1350 "
Aromatic C-H str. 3060.8 3080-3030 435
C-H i.p. def. 1126.4 1125-1090 "
1062.7 1070-1000 "
C-H o.o.p. def. 833.2 835-810 "
Pyrazole C=N str. 1598.9 1650-1600 434
moiety C=C str. 1498.6 1585-1480 "
C-N str. 1249.8 1350-1200 "
C-Br 534 600-500 "
Ether C-O-C (asym.) 1216.1 1275-1200 "
C-O-C (sym.) 1024.1 1075-1020 "
Pyrazoline C=N str. 1581.5 1627-1580 437
C-H def. 688.5 698-690 "
N
N
O
CH3
NN
Br
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PMR SPECTRAL STUDY OF 1,N-PHENYL-3-(ρ-BROMOPHENYL)-5-(1',N-PHENYL-3'-
ρ-ANISYL-PYRAZOL-4'-YL)-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.16 Jqp=16.8,     Jqo=6.7 1H d. doublet CHq
2 3.75 Jpq=16.8,    Jpo=12.0 1H d. doublet CHp
3 3.86 3H singlet Ar-OCH3
4 5.47 Jop=12.0,     Joq=6.7 1H d. doublet CHo
5 6.80 1H triplet Ar-Hm
6 7.03 Jgf=8.4 2H doublet Ar-Hgg'
7 7.08 Jhi=8.4 2H doublet Ar-Hhh'
8 7.16-7.23 3H multiplet Ar-Hj Ar-Hk, Ar-Hd
9 7.35 2H triplet Ar-Hc, Ar-He
10 7.47 Jfg=8.4 2H doublet Ar-Hff'
11 7.55 Jih=8.4 2H doublet Ar-Hii'
12 7.60 2H doublet Ar-Hl, Ar-Hn
13 7.70-7.74 3H multiplet Ar-Ha, Ar-Hb, CHx
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m/z = 550 (m+1)
EXPANDED AROMATIC REGION
70
Comp.
No.
1
TABLE NO. 5 : PHYSICAL CONSTANTS OF 1,N-PHENYL-3-ARYL-5-(1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-
4'-YL)-PYRAZOLINES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
5a C6H5- C31H26N4O 470.5 154 0.61 62 11.91 11.88
5b 4-NH2-C6H4- C31H27N5O 485 145 0.52 66 14.42 14.37
5c 3-NH2-C6H4- C31H27N5O 485 133 0.48 62 14.42 14.36
5d 4-Br-C6H4- C31H25N4OBr 549 160 0.55 68 10.20 10.15
5e 4-Cl-C6H4- C31H25N4OCl 505 148 0.42 70 11.09 11.03
5f 4-F-C6H4- C31H25N4OF 488 155 0.49 65 11.47 11.42
5g 4-OCH3-C6H4- C32H28N4O2 500 164 0.65 64 11.19 11.16
5h 4-CH3-C6H4- C32H28N4O 484 158 0.74 65 11.56 11.51
5i 4-NO2-C6H4- C31H25N5O3 515 175 0.69 70 13.58 13.52
5j 3-NO2-C6H4- C31H25N5O3 515 184 0.45 61 13.58 13.54
5k 4-OH-C6H4- C31H26N4O2 486 150 0.44 71 11.51 11.47
5l 2-OH-C6H4- C31H26N4O2 486 170 0.54 60 11.51 11.49
*TLC Solvent System : Ethylacetate : Hexane (2 : 8)
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PART - III
STUDIES ON
CYANOPYRIDINES
INTRODUCTION
Pyridine, which belongs to an important group of heterocyclic compounds
has been extensively explored for its applications in the field of medicine,
agriculture and industrial chemistry. Pyridine 3-carboxamide occurs as a
component of the structure of the important coenzymes NADP + (I). One of the
B2 complex of vitamins, occurs in red blood carpuscles and participates in
biochemical redox reaction.
The availability of 3-cyanopyridine, nicotinamide and nicotinic acid make
possible their use as synthetic intermediates.
SYNTHETIC ASPECT :
Different methods for preparation of 3-cyanopyridines are available in
literature146-152. The well known method is
Cyanopyridines...
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N
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1. Sakurai and Midorikwa153,154 have reported that malononitrile reacts
with α,β-unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted
pyridines (II).
MECHANISM
The reaction proceeds through conjugated addition of active methylene
compounds to the α,β-unsaturated system as shown below.
THERAPEUTIC IMPORTANCE
Cyanopyridines have attracted considerable attention as they appeared of
interest to possess antibacterial, anticholestermic, antifungal, antihypertensive
and antidiabetic activities. Kurt et. al.155 have studied the analgesic activity of
substituted 3-cyanopyridines. Hironori et al.156  have prepared cyanopyridines
and screened for their large conductance calcium acetivated potassium channel
opener activity.
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N. Latif and co-workers157 have reported the antibacterial and antifungal
activity of 2-amino-3-cyano-4,6-disubstituted pyridines. U. Teu and co-
workers158 have shown cyanopyridine as agrochemical fungicidies. M. Bernard
and co-workers159 reported the anticonvulsant properties of 3-cyanopyridines.
Bhatt et. al.160 have prepared 3-cyanopyridines as an immunosuppressive agent.
H. Yoshida et. al.161 have studied the antihistamic and antiallergic activity
of 3-cyanopyridine derivatives. Gadaginamath and co-workers162 have
synthesised various cyanopyridyl derivatives (III) and documented their variety
of biological activities.
Manna Fedele and co-workers163 have reported the antiinflammatory
activity of 3-cyanopyridines. Abd El-Galil and co-workers164 have prepared 3-
cyanopyridines (IV) and studied their pharmacological activity.
Hammana Abou and co-workers165 have studied the anticancer and
antiHIV activity of 3-cyanopyridines. Abdallah Navine et. al.166 have prepared
cyanopyridine derivatives which showed analgesic and antiinflammatory activity.
NNNH2
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S. V. Roman et. al.167 have investigated 2-amino-3-cyanopyridine
derivatives and reported their biological activity. El-Taweel and co-workers168
have described cyanopyridine derivatives (V) and showed their significant
biological activity.
Abu and co-workers169 have determined novel fused cyanopyridines (VI)
for the treatment and preparation of systemic fungal infection.
Hussan M. and co-workers170 have prepared 3-cyanopyridines (VII) and
reported their pharmacological activity. Pyachenko U. D. and co-workers171
have shown some cyanopyridines (VIII) which are useful in treatment of retroviral
disease.
Cyanopyridines...
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Streightoff172 and seydal173 have studied the bacteriostatic effect of some
substituted 3-cyanopyridines. Francis and co-workers174 have studied the effect
of some substituted pyridines on the growth of the walker carcinosarcome-256
in tissue culture. Barton et al.175 have reported fungicidal and insecticidal
proper ties. W. Hoefl ing and co-workers176 have documented 3-and 4-
cyanopyridineds as tuberculosis arresting agents.
K. Kadlec and Hanslian177 showed that 2-methyl-3-nitro-4-methoxyethyl-
5-cyano-6-chloro pyridines caused occupational eczema in vitamin B6 factory
workers. Rigterink and Raymond178 have suggested the pesticidal activity of 3-
cyanopyridines. N-substituted 2-aminopyridines which possess anticonvulsant
property have prepared by M. R. Pavia and co-workers.179 3-cyanopyridines
reported by L. Castedo et al.180 showed a minimum inhibitory concentration
of 1.56 µg/ml against S. aureus. W. Von Benbenburg and co-workers181 have
synthesised 2-amino-3,6-disubstituted pyridines as antiepileptic agents.
CONTRIBUTION FROM OUR LABORATORY
Akhil Bhatt and co-workers182 have synthesised cyanopyridines as
potent ia l  ant imicrobia l  agents .  R.  C.  Khunt  e t  a l .183 have screened
cyanopyridine derivatives used as biologically active agents. Synthesis and
antimicrobial activity of cyanopyridines showed by B. P. kansagara et al.184 J.
R. Patel and co-workers185 have prepared cyanopyridines bearing 2-chloro-6-
bromoquinoline nucleus as potential anticancer agents.
Synthesis and biological evaluation of cyanopyridines suggestd by Pankaj
Patel and co-workers186. Rajeev Doshi and co-workers187 have described some
novel cyanopyridines as a new class of potential antitubercular agents.
Cyanopyridines have screened by A. V. Dobariya et al.188 and showed their
significant biological activity. B. P. Kansagara and co-workers189 have reported
cyanopyridines having a quinoline nucleus and compounds found to be an
antimicrobial (IX).
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Adriano Afouso et al.190 have suggested that cyanopyridines are Fernesyl
Protein transferase inhibitors. Hussain and co-workers190 have prepared
cyanopyridines as a antimicrobial agents. Wu Wenxue et al.192 have reported
cyanopyridines as histamine H3 antagonists. Saudi Manal N. S. et al.
193 have
found that cyanopyridines have fasciolicidal property.
Thus, diverse biological activities have been encountered in compounds
containing cyanopyridine ring system. To further assess the potential of such
type of compounds, study of cyanopyridines have been carried out as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
AMINO-3-CYANO-4-[1',N-PHENYL-3'-ρ-ANISYL-
PYRAZOL-4'-YL]-6-ARYL-PYRIDINES
N
N
NH2
N
R
Cl
O
CH3
(IX) R = Aryl
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-3-CYANO-
4-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-6-ARYL-PYRIDINES
In the past years, considerable evidence has been accumulated to
demonstrate the efficiency of cyanopyridines. To further assess the potential of
such a class of compounds cyanopyridine derivatives of type (VI) have been
synthesised by condensation of malanonitrile and ammonium acetate with 1-
aryl-3-[1',N-Phenyl-3'-ρ-anisyl-pyrazol-4'-yl]-2-propene-1-ones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. wehen R=ρ-hydroxyphenyl, molecular
weight=459, m/z=460 (m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-3-CYANO-
4-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-6-ARYL-PYRIDINES
(A) Synthesis of N-Aminophenyl-α-methyl-ρ-anisyl azomethine
See Part - I, Section - I(A).
(B) Synthesis of 1,N-Phenyl-3-ρ-anisyl-4-formyl pyrazole
See Part - I, Section - I(B).
(C) Synthesis of 1-Phenyl-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-yl)-2-
propene-1-one
See Part - I, Section - I(C).
(D) Synthesis of 2-Amino-3-cyano-4-[1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-
yl]-6-phenyl-pyridine
A mixture of 1-Phenyl-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-yl)-2-propene-
1-one (3.80 g, 0.01 M), malanonitrile (0.66 g, 0.01 M) and ammonium acetate
(6.61 g, 0.08 M) dissolved in absolute alcohol was refluxed for 10 hrs. The
reaction product was poured into ice, crude product was isolated, crystallised
from ethanol. Yield 65%, m.p. 178oC. (Anal. Found : C, 75.78 H, 4.70; N,
15.73%; C28H21N5O Requires: C, 75.83; H, 4.77; N, 15.79%).
Similarly other cyanopyridines have been obtained. The physical data are
recorded in Table No. 6
(E) Antimicrobial activity of 2-Amino-3-cyano-4-[1',N-phenyl-3'-ρ-
anisyl-pyrazol-4'-yl]-6-aryl-pyridines
Antimicrobial testing was carried out as described in Part - I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 6
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IR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-(1',N-PHENYL-3'-ρ-ANISYL-
PYRAZOL-4'-YL)-6-PHENYL PYRIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2950.8 2975-2950 434
-CH3 C-H str. (sym.) 2860.2 2880-2860 "
C-H def. (asym.) 1463.9 1470-1435 "
C-H def. (sym.) 1342.4 1385-1350 "
Aromatic C-H str. 3068.5 3080-3030 435
C-H i.p. def. 1004.8 1070-1000 "
C-H o.o.p. def. 815.8 835-810 "
Pyrazole C=N str. 1593.1 1650-1600 434
moiety C=C str. 1558.4 1585-1480 "
C-N str. 1317.3 1350-1200 "
Ether C-O-C (asym.) 1276.8 1275-1200 "
C-O-C (sym.) 1049.2 1075-1020 "
Pyridine ring C=N str. 2204.5 2240-2120 "
C=N str. 1633.6 1680-1600 "
C=C str. 1076.2 1075-1020 "
N-H str. (-NH2) 3350.1 3350-3250 "
N
N
O
CH3
N
NH2
N
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PMR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-(1',N-PHENYL-3'-ρ-ANISYL-
PYRAZOL-4'-YL)-6-PHENYL PYRIDINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.82 3H singlet Ar-OCH3
2 6.93 Jgf=9.0 2H doublet Ar-Hgg'
3 7.17 Jfg=9.0 2H doublet Ar-Hff'
4 7.34 1H triplet Ar-Hd
5 7.44-7.52 6H multiplet Ar-Hj-l,Ar-Hc,
Ar-He, CHy
6 7.73 2H doublet Ar-Hh, Ar-Hi
7 7.83 2H doublet Ar-Ha, Ar-Hb
8 8.52 1H singlet CHx
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6a C6H5- 2204.5
6b 4-NH2-C6H4- 2206
6c 3-NH2-C6H4- 2212
6d 4-Br-C6H4- 2202.6
6e 4-Cl-C6H4- 2200.4
6g 4-F-C6H4- 2216
6h 4-OCH3-C-6H4- 2204
6i 4-CH3-C6H4- 2208
6j 4-NO2-C6H4- 2206
6m 3-NO2-C6H4- 2210
6n 4-OH-C6H4- 2202
6o 2-OH-C6H4- 2212
Sr.
 No. R
C=N str.
Cyanopyridines
EXPANDED AROMATIC REGION
IR SPECTRAL DATA OF 2-AMINO-3-CYANO-4-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-
4'-YL]-6-ARYL-PYRIDINES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
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TABLE NO. 6 : PHYSICAL CONSTANTS OF 2-AMINO-3-CYANO-4-(1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-
4'-YL)-6-ARYL-PYRIDINES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
6a C6H5- C28H21N5O 443 178 0.46 65 15.79 15.76
6b 4-NH2-C6H4- C28H22N6O 458.5 184 0.54 62 18.33 18.28
6c 3-NH2-C6H4- C28H22N6O 458.5 180 0.42 70 18.33 18.27
6d 4-Br-C6H4- C28H20N5OBr 522 181 0.49 69 13.41 13.38
6e 4-Cl-C6H4- C28H20N5OCl 478 220 0.64 74 14.65 14.60
6f 4-F-C6H4- C28H20N5OF 461 202 0.71 71 15.18 15.14
6g 4-OCH3-C6H4- C29H23N5O2 473.5 173 0.54 71 14.79 14.73
6h 4-CH3-C6H4- C29H23N5O 457.5 188 0.59 68 15.31 15.29
6i 4-NO2-C6H4- C28H20N6O3 488 190 0.45 75 17.20 17.17
6j 3-NO2-C6H4- C28H20N6O3 488 185 0.76 64 17.20 17.15
6k 4-OH-C6H4- C28H21N5O2 459 222 0.55 64 15.24 15.20
6l 2-OH-C6H4- C28H21N5O2 459 195 0.41 66 15.24 15.18
*TLC Solvent System : Ethylacetate : Hexane (2 : 8) (6a-6l)
(3 : 7) (6e, 6g)
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PART - IV
STUDIES ON
CYANOPYRIDONES
INTRODUCTION
Pyridones,  which belongs to an impor tant group of heterocycl ic
compounds have been extensively explored for their applications in the field of
medicine. Pyridones, with a carbonyl group at position 2 (I) have been subject
of extensive study in recent past. Numerous reports have appeared in the
literature which highlight their chemistry and use.
2-Pyridones are derivatives of pyrimidines with carbonyl group at 2-position
(I). Some 2-pyridones are physiologically as well as pharmacologically important
which are as under. eg. amrinone (II), ciclopirox (III) and methylprylon (IV).
SYNTHETIC ASPECTS
Different methods for preparation of 2-pyridones are as follows :
1. K. Folkers and S. A. Harris194 have synthesised 3-cyano-2-pyridone by
the condensation of cyanoacetamide with 1,3-diketone or 3-ketoester.
( I )
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2. M. A. Sluyter and co-workers195 have prepared fused 2-pyridones.
3. G. Simchen and G. Entemman196 have synthesised 2-pyridone in which
the ring nitrogen comes from a nitrile group in acyclic precursor.
THERAPEUTIC IMPORTANCE
Pyridone derivatives have been found to possess variety of therapeutic
activities as shown below.
1. Anticancer197
2. Herbicidal198
3. Pesticidal199,200
4. Antimicrobial201
5. Angitensin II antagonist202-204
6. Antiviral205
7. AntiHIV206
Peter and co-workers207 have prepared pyridinylmethyl substituted
pyridines and pyridones as angitensin II antagonist. H. Posnes208 synthesised
2-pyridones and 2-pyrones as physiologically active compounds. Mukhtar
Hussain Khan and co-workers209,210 have prepared 2-pyridone derivatives
(V) and (VI) which possess insecticidal and pesticidal activity.
Cyanopyridones...
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Morishita Koji et. al.211 have synthesised m-(2-oxo-1,2-dihydropyridyl) urea
derivatives (VII) possessing cholesterol acyltransterase (ACAT) inhibitory activity
and are useful for the treatment of hyperlipidemia and arteriosclerosis.
Collins et. al.212 prepared heteroaryl pyridones as GABA α2/α3 ligands
(VIII). Pednekar213 synthesised fused 2-pyridone derivatives (IX), (X) and (XI)
as useful heterocyclic moieties as they possess broad spectrum of biological
activities such as antiviral, CNS depressant, bactericidel and ulcer inhibitor.
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Moreover, several co-workers have prepared 2-pyridones as S3 site of
thrombin inh ib i tor214,  herb ic ida l215,  SH2 domain inh ib i tor
216,
antimicrobial217, GABA-A receptor218 and antiinflammatory219.
Upadhyay and co-workers220 have synthesised cyanopyridone derivatives
which showed antifungal and antileishmanial activities. E. Amer221 prepared
3-cyano-2-pyridone derivatives (XII) displaying high antimicrobial activity. Abou
El-Fotooh and co-workers222 have demonstrated pyridones (XIII) as anticancer
agent.
M. G. Nizamuddin et. al.223 have prepared cyanopyridone derivatives (XIV)
and documented their antifungal activity.
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Ar Ar
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( XIV ) R & R1 = Aryl
Cyanopyridones...
X = F, Cl, Br
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Cyanopyridones...
Tanaka Akira et. al.224 have prepared pyrazolo pyridone derivatives (XV).
With an intension of preparing the compounds possessing better therapeutic
activity, we have undertaken the preparation of cyanopyridones which have
been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
CYANO-4-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-
YL]-6-ARYL-1,2-DIHYDRO-2-PYRIDONES
N
NN
R
R1
O
( XV )
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-[1',N-
PHENYL-3'-ρ -ANISYL-PYRAZOL-4'-YL]-6-ARYL-1,2-DIHYDRO-2-
PYRIDONES
Pyridone derivatives have remarkable therapeutic activity. Taking this into
consideration, we have undertaken the preparation of pyridone derivatives by
the condensation of chalcones of type (I) with ethylcyanoacetate in presence of
ammonium acetate as shown under.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry. In mass spectrometry the m/z value indicate
the molecular weight, i.e. when R = ρ-bromophenyl molecular weight = 523,
m/z=523 (m).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
N
N
O
R
O
CH3
R = ArylType (VII)
N
N
O
CH3
NH
O
R
N
CN-CH2-COOC2H5
CH3COONH4
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-[1',N-
PHENYL-3'-ρ -ANISYL-PYRAZOL-4'-YL]-6-ARYL-1,2-DIHYDRO-2-
PYRIDONES
(A) Synthesis of N-Aminophenyl-α-methyl-ρ-anisyl azomethine
See Part - I, Section - I(A).
(B) Synthesis of 1,N-Phenyl-3-ρ-anisyl-4-formyl pyrazole
See Part - I, Section - I(B).
(C) Synthesis of 1,(ρ-Bromophenyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl)-2-propene-1-one
See Part - I, Section - I(C).
(D) Synthesis of 3-Cyano-4-[1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-yl]-6-(ρ-
bromophenyl)-2-pyridone
A mixture of 1-(ρ-bromophenyl)-3-(1',N-phenyl-3'-ρ-anisyl-pyrazol-4'-yl)-
2-propene-1-one (4.59 g, 0.01 M), ethylcyanoacetate (1.13 g, 0.01 M) and
ammonium acetate (5.92 g, 0.08 M) in absolute alcohol was refluxed for 10 hrs.
The reaction product was poured into ice, filtered and crystallised from ethanol.
Yield 68%, m.p. 135oC. (Anal. Found : C, 64.21 H, 3.64; N, 10.65%;
C28H19N4O2Br Requires: C, 64.26; H, 3.66; N, 10.70%).
Similarly other substituted pyridones have been prepared. The physical
data are recorded in Table No. 7
(E) Antimicrobial activity of 3-Cyano-4-[1',N-phenyl-3'-ρ-anisyl-pyrazol-
4'-yl]-6-aryl-2-pyridones
Antimicrobial testing was carried out as described in Part - I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 7
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IR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL)-
6-(ρ-BROMOPHENYL)-1,2-DIHYDRO-2-PYRIDONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2950.9 2975-2950 434
-CH3 C-H str. (sym.) 2862.2 2880-2860 "
C-H def. (asym.) 1465.8 1470-1435 "
C-H def. (sym.) 1380.9 1385-1350 "
Aromatic C-H str. 3051.2 3080-3030 435
C-H i.p. def. 1107.1 1125-1090 "
1070.4 1070-1000 "
C-H o.o.p. def. 819.7 835-810 "
Pyrazole C=N str. 1606.6 1650-1600 434
moiety C=C str. 1496.7 1585-1480 "
C-N str. 1256.6 1350-1200 "
C-Br str. 526.5 600-500 "
Ether C-O-C (asym.) 1234.4 1275-1200 "
C-O-C (sym.) 1022.2 1075-1020 "
Pyridone ring C=N str. 2219.9 2240-2120 "
C=O str. 1656.7 1760-1655 "
N-H str. 3413.8 3450-3250 "
N-H def. 1581.5 1650-1580 "
N
N
O
CH3
NH
O
N
Br
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PMR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL)-
6-(ρ-BROMOPHENYL)-1,2-DIHYDRO-2-PYRIDONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.94 3H singlet Ar-OCH3
2 6.73 1H singlet CHy
3 7.09 Jgf=8.7 2H doublet Ar-Hgg'
4 7.31 Jhi=8.7 2H doublet Ar-Hhh'
5 7.52 Jfg=8.7 2H doublet Ar-Hff'
6 7.62 3H doublet Ar-Hc-e
7 7.69 Jih=8.7 2H doublet Ar-Hii',Ar-Ha,
Ar-Hb
7 8.65 1H singlet CHx
N
N
O
CH3
NH
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N
Br
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c b
f
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x
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7a C6H5- 2204 1658
7b 4-NH2-C6H4- 2202 1654
7c 3-NH2-C6H4- 2233 1649
7d 4-Br-C6H4- 2219.9 1656.7
7e 4-Cl-C6H4- 2218 1652
7g 4-F-C6H4- 2222 1660
7h 4-OCH3-C6H4- 2210 1658
7i 4-CH3-C6H4- 2216 1649
7j 4-NO2-C6H4- 2212 1650
7m 3-NO2-C6H4- 2218 1652
7n 4-OH-C6H4- 2214 1656
7o 2-OH-C6H4- 2212 1651
Sr.
 No. R
C=O str.
Cyanopyridones
EXPANDED AROMATIC REGION
IR SPECTRAL DATA OF 3-CYANO-4-[1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL]-
6-ARYL-1,2-DIHYDRO-2-PYRIDONES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
C=N str.
Cyanopyridones
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TABLE NO. 7 : PHYSICAL CONSTANTS OF 3-CYANO-4-(1',N-PHENYL-3'-ρ-ANISYL-PYRAZOL-4'-YL)-6-
ARYL-1,2,DIHYDRO-2-PYRIDONES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
7a C6H5- C28H20N4O2 444 158 0.51 60 12.60 12.57
7b 4-NH2-C6H4- C28H21N4O2 459 150 0.39 61 15.24 15.20
7c 3-NH2-C6H4- C28H21N4O2 459 152 0.46 68 15.24 15.21
7d 4-Br-C6H4- C28H19N4O2Br 523 135 0.62 68 10.70 10.65
7e 4-Cl-C6H4- C28H19N4O2Cl 479 165 0.71 64 11.70 11.67
7f 4-F-C6H4- C28H19N4O2F 462 206 0.45 72 12.11 12.07
7g 4-OCH3-C6H4- C29H22N4O3 474 159 0.55 68 11.81 11.77
7h 4-CH3-C6H4- C29H22N4O2 458 161 0.59 65 12.22 12.20
7i 4-NO2-C6H4- C28H19N5O4 484 181 0.47 62 14.31 14.28
7j 3-NO2-C6H4- C28H19N5O4 484 155 0.74 71 14.31 14.29
7k 4-OH-C6H4- C28H20N4O3 460 168 0.65 64 12.17 12.13
7l 2-OH-C6H4- C28H20N4O3 460 170 0.50 74 12.17 12.11
*TLC Solvent System : Ethylacetate : Hexane (2 : 8)
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PART - V
STUDIES ON
THIAZOLIDINONES
INTRODUCTION
Thiazolidinones, which belong to an important group of heterocyclic
compounds have been extensively explored for their applications in the field of
medicine. Thiazolidinones, with a carbonyl group at position 2(I), 4(II) or 5(III)
have been subject of extensive study in recently.
Substitutent in the 2,3 and 5 position may be varied, but the greatest
difference in structure and properties is exerted by the groups attached to carbon
atom at the 2-position and to nitrogen atom at the 3-position. The cyclic structure
was assigned after recognisation of mercaptoacetic acid as a primary product of
hydrolysis of 3-phenyl-2-phenylamino-4-thiazolidinones225.
SYNTHETIC ASPECTS
Several methods for the preparation of 4-thiazolidinones are narrated in
literature226-234.
1. R. Nath and K. Shankar235 have prepared 4-thiazolidinone by cyclisation
of N-aryl-N'-(2'-pyridyl) thiocarbamide with chloroacetic acid.
(I) (II) (III)
N
H
S O
NH
S
O
N
H
SO
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2. I .  D. Shah and J.  P.  Tr ivedi236 synthesised thiazol idinones f rom
4-arylthiosemicarbazones by condensed them with chloroacetic acid ,
α-bromopropionic acid and α-bromophenyl acetic acids.
3. M. Saeda et. al.237 synthesised some new thiazolidinones.
MECHANISM
The reaction of 4-thiazolidinones proceeds by the attacks of the chloroacetic
acid upon the C=S group. The tautomerism takes place with removal of HCl
followed by removal of water and subsequent cyclisation.
R' NH
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NH
R
Cl.CH2COOH
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N
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THERAPEUTIC IMPORTANCE
Much research has been carried out with an aim to finding therapeutic
values of thiazolidinone moiety since their discovery. The thiazolidinones,
substituted at 2- and 3-position are reported to exhibit a wide variety of biological
activity.
1. Anthelmintics238,239
2. Cardiovascular240
3. Mosquito repellant241
4. Antiviral242
5. Antitumor243
6. Local anaesthetic244
7. Antimicrobial245
8. Antitubercular246,247
9. Anti HIV and anticancer248
10. Insecticidal249
11. Herbicidal250
Hassan et. al.251 have prepared 2-imino-4-thiazolidinones which have been
found to possess antimicrobial activity. K. Mogilaiah and co-workers252,253
isolated some 4-thiazolidinone derivatives and tested their antibacterial activity.
G. S. Gadaginamath et. al.254 also prepared thiazolidinone derivatives as
antimicrobial agent. R. S. Lodhi and co-workers255 have synthesised and studied
antimicrobial, antiinflammatory and analgesic property of 4-thiazolidinone and
aryledene derivatives (VII).
Thiazolidinones...
(VII)
N
N
NH N
S
R1
O
ZO
R1 = (un) substituted aryl
Z = H2
Z = CH2R2
R1,R2 = Substituted aryl
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Pawar and co-workers256 reported synthesis and in vitro antibacterial
activity of some 4-thiazolidinone derivatives.
CONTRIBUTION FROM OUR LABORATORY
Parikh et. al. have synthesised variety of 4-thiazolidinone derivatives
bear ing  S- t r iaz ine257,  benzoy lamino ace tamido258,  su lphonamido
benzylamino259, phthalazine-1-yl-amino260, aryl substituted hydroxy and β,β-
dichloro ethylamino phenyl moieties of 4-thiazolidinone ring system and have
reported as potent antimicrobial agents. H. H. Parekh and co-workers have
synthesised 4-thiazolidinones bearing dapson261, s-triazine262, acridine-9-
yl263, thymoloxyacetamido264, 6-hydroxy pyrimidine265, 9-thiazolidinone ring
system  having antimicrobial activity.
Moreover, A. J. Baxi et. al.266 have synthesised some new 4-thiazolidinones
which shows antiHIV, antitumor and antihypertensive activities. H. H. Parekh
and co-workers267,268 have synthesised new bis 4-thiazolidinones and studied
their biological activity. Recently, A. R. Parikh and co-workers269 have assessed
thiazolidinone derivatives bearing 7-methoxyquinoline nucleus for antimicrobial
activity.
G. Bhawna et. al.270 have synthesised thiazolidinone derivatives and
compared their antiinflammation potency, ulcerogenic liability, cardiovascular
and CNS effect. In other study, some thiazolidinone derivatives have been found
to be promising antibacterial agent271,272.
Siddique, Mohammad et. al.273 have prepared substituted thiazolidinones
and reported their antibacterial, antifungal, antithyroid and amoebicidal
properties (VIII). S. K. Srivastava and co-workers274 have suggested new
thiazolidinones (IX) and reported their diuretic, analgesic and antimicrobial
activities.
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Thiazolidinones...
Considerable evidence has been accumulated to demonstrate the wide
applications of thiazolidinone derivatives. In view of these findings,it appeared
of interest to synthesise newer thiazolidinone derivatives with better potency.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
ARYLIMINO-3,N-ARYL-5-[1',N-PHENYL-3'-ρ-ANISYL-
4'-PYRAZOLYL-METHINO]-4-THIAZOLIDINONES
N
S
O
S
R5
R4
R3
R1
R2
N
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HR
N
H
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R
O
N
N
N
(IX)
R1 = OH, R2, R4, R5 = H, R3 = Me
(VIII)
R = Aryl
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5-[1',N-PHENYL-3'-ρ-ANISYL-4'-PYRAZOLYL-METHINO]-4-
THIAZOLIDINONES
Recently, much interest has been focused on the synthesis and biodynamic
activities of arylidene and it is a good synthon for constructing various
heterocyclic rings. With a view of obtaining compounds having better therapeutic
activities, we have synthesised 2-arylimino-3,N-aryl-5-[1',N-phenyl-3'-ρ-anisyl-
4'-pyrazolylmethino]-4-thiazolidinones by the condensation of 1,N-phenyl-3-ρ-
anisyl-4-formyl-pyrazole with various thiazolidinone compounds.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R=ρ-anisyl, molecular weight=588,
m/z=589 (m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard drugs.
N
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R = ArylType (VIII)
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REACTION SCHEME
Type (VIII) R = Aryl
N
N
O
CH3
N
S
N
R
R
O
gl. ACOH
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H
O
CH3COONa
N
S
N
R
R
O +
gl. ACOH
CH3COONa
ClCH2COOH
NH
R
S
NHR
Absolute alcohol
R2   NH2 + CS2
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5-[1',N-PHENYL-3'-ρ -ANISYL-4'-PYRAZOLYLMETHINO]-4-
THIAZOLIDINONES
(A) Preparation of N1,N3-Bisaryl thiourea275
In a round bottom flask, a mixture of arylamine (0.2 M), carbon disulphide
(7 ml, 0.1 M) and absolute alcohol (20 ml) was heated on waterbath for 5-6
hrs., on completion of reaction, the excess of carbon disulphide and alcohol
was removed by distillation. The product was treated with dilute hydrochloric
acid to remove excess of amine present and crude product was isolated and
crystallised from ethanol.
(B) Preparation of 2-Arylimino-3-aryl-5H-4-thiazolidinones276
A solution of N1, N3-bisaryl thiourea (0.01 M) and chloroacetic acid (0.94
g, 0.01 M) in glacial acetic acid (15 ml) was refluxed with fused sodium acetate
(1.25 g, 0.015 M) for 5 hrs. The reaction product was poured in water, kept
overnight, crude product was isolated and crystallised from ethanol.
(C) Preparation of 2-(ρ-Anisylimino)-3,N-(ρ-anisyl)-5-(1',N-phenyl-3'-ρ-
anisyl-4'-pyrazolylmethino)-4-thiazolidinones
A mixture of 2-(ρ-anisylimino)-3-(ρ-anisyl)-5H-4-thiazolidinone (3.28 g, 0.01 M),
1,N-phenyl-3-ρ-anisyl-4-formyl-pyrazole (2.78 g, 0.01 M) and fused sodium
acetate (1.25 g, 0.015 M) was refluxed in glacial acetic acid (15 ml) for 4-5 hrs.,
cooled, poured into water and treated with ammonia to remove excess of glacial
acetic acid. The product was isolated and crystallised from ethanol. Yield 75%,
m.p. 190oC. (Anal. Found : C, 66.33 H, 4.73; N, 9.49%; C34H28N4O4S
Requires: C, 66.37; H, 4.79; N, 9.52%).
Similarly other substituted thiazolidinones have been prepared. The physical
data are recorded in Table No. 8
(D) Antimicrobial activity of 2-Arylimino-3,N-aryl-5-(1',N-phenyl-3'-ρ-
anisyl-4'-pyrazolylmethino)-4-thiazolidinones
Antimicrobial testing was carried out as described in Part - I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 8
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IR SPECTRAL STUDY OF 2-(ρ-ANISYLIMINO)-3,N-(ρ-ANISYL)-5-(1',N-PHENYL-3'-
ρ-ANISYL-4'-PYRAZOLYLMETHINO)-4-THIAZOLIDINONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2964.0 2975-2950 434
-CH3 C-H str. (sym.) 2879.5 2880-2860 "
C-H def. (asym.) 1434.9 1470-1435 "
C-H def. (sym.) 1363.6 1385-1350 "
Aromatic C-H str. 3053.1 3080-3030 435
C-H i.p. def. 1105.1 1125-1090 "
1053.1 1070-1000 "
C-H o.o.p. def. 833.2 835-810 "
Pyrazole C=N str. 1596.9 1650-1600 434
moiety C=C str. 1500.5 1585-1480 "
C-N str. 1253.6 1350-1200 "
Ether C-O-C (asym.) 1213.1 1275-1200 "
C-O-C (sym.) 1028.0 1075-1020 "
Thiazolidinone C=O str. 1706.9 1760-1655 434
S-C=N str. 1629.7 1640-1605 436
C-S-C str. 688 700-600 "
Arylidene =CH i.p. 1363.6 1420-1290 "
(overlapped)
1672 1690-1600 "
N
N
O
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N
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O
O CH3
O CH3
109
PMR SPECTRAL STUDY OF 2-(ρ-ANISYLIMINO)-3,N-(ρ-ANISYL)-5-(1',N-PHENYL-
3'-ρ-ANISYL-4'-PYRAZOLYLMETHINO)-4-THIAZOLIDINONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.83 3H singlet Ar-OCH3
2 3.84 3H singlet Ar-OCH3
3 3.86 3H singlet Ar-OCH3
4 6.92 4H doublet Ar-Hhh'
Ar-Hkk'
5 7.01 Jjk=6.6 2H doublet Ar-Hjj'
6 7.04 Jih=6.6 2H doublet Ar-Hii'
7 7.34 1H doublet Ar-Hd
8 7.37 Jgf=8.7 2H doublet Ar-Hgg'
9 7.48 1H triplet Ar-Hc, Ar-He
10 7.61 Jfg=8.7 2H doublet Ar-Hff'
11 7.75 2H doublet Ar-Ha, Ar-Hb
12 7.83 1H singlet CHy
13 8.08 1H singlet CHx
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8a C6H5- 1714
8b 4-COOH-C6H4- 1708
8c 4-Cl-C6H4- 1712
8d 3,4-(Cl)2-C6H3- 1716
8e 4-F-C6H4- 1710
8f 4-OCH3-C6H4- 1706
8g 4-CH3-C6H4- 1703
8h 3-CH3-C6H4- 1708
8i 2-CH3-C6H4- 1706
8j 4-N02-C6H4- 1700
8k 3-N02-C6H4- 1708
8l 2-N02-C6H4- 1716
Sr.
 No. R
C=O str.
Thiazolidinones
EXPANDED AROMATIC REGION
IR SPECTRAL DATA OF 2-ARYLIMINO-3,N-ARYL-5-[1',N-PHENYL-3'-ρ-ANISYL-4'-
PYRAZOLYLMETHINO]-4-THIAZOLIDINONES
Instrument : SHIMADZU-FT-IR-8400 Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
111
N
N
O
C
H
3
N
S
N
O
OC
H
3
OC
H
3
m
/z
 =
 5
8
9
 (
m
+
1
)
112
113
N
N
O
C
H
3
S
N
N
O
CH
3
O
C
H 3
O
H
C
S
N N
O
C
H 3
C
H
3
O
C
H 3
N
N
O
C
H
3
O
N
N
O C
H 3
C
H
S
N
NH
O
O
H
N
N
O
m
/z
 =
 3
06
 (m
 -1
 )
m
/z
 =
 2
39
 
m
/z
 =
 2
54
 
m
/z
 =
 2
74
 
m
/z
 =
 1
07
 
m
/z
 =
 3
19
B
A
SE
 P
EA
K
+
+
+
+
+
+
+
+
+
+
m
/z
 =
 5
89
(m
 +
1 
)
Comp.
No.
1
TABLE NO. 8 : PHYSICAL CONSTANTS OF 2-ARYLIMINO-3,N-ARYL-5-(1',N-PHENYL-3'-ρ -ANISYL-4'-
PYRAZOLYLMETHINO)-4-THIAZOLIDINONES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
8a C6H5- C32H24N4O2S 529 180 0.45 75 10.60 10.55
8b 4-COOH-C6H4- C34H24N4O6S 617 185 0.61 68 9.09 9.04
8c 4-Cl-C6H4- C32H22N4O2S(Cl)2 597.5 214 0.42 69 9.38 9.34
8d 3,4-(Cl)2-C6H3- C32H20N4O2SCl4 666 202 0.56 71 8.41 8.38
8e 4-F-C6H4- C32H22N4O2SF2 565 235 0.51 71 9.92 9.88
8f 4-OCH3-C6H4- C34H28N4O4S 589 190 0.42 75 9.52 9.47
8g 4-CH3-C6H4- C34H28N4OS 557 188 0.59 70 10.06 10.01
8h 3-CH3-C6H4- C34H28N4O2S 557 195 0.74 66 10.06 10.02
8i 2-CH3-C6H4- C34H28N4O2S 557 211 0.70 65 10.06 10.04
8j 4-NO2-C6H4- C32H22N6O6S 619 198 0.62 70 13.59 13.52
8k 3-NO2-C6H4- C32H22N6O6S 619 171 0.65 74 13.59 13.56
8l 2-NO2-C6H4- C32H22N6O6S 619 225 0.59 67 13.59 13.54
*TLC Solvent System : Ethylacetate : Hexane (2 : 8) (8a-8l)
(3 : 7) 8e
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B :
STUDIES ON
TRIAZOLES
INTRODUCTION
Triazoles have occupied an important place in the pharmaceutical industry.
Triazole molecule is having following isomers  viz. v-triazoles or 1,2,3-triazoles
(I), s-triazoles or 1,2,4-triazoles (II) and their benzo derivatives. Most of the
work is reported on 1,2,4-triazoles or s-triazoles.
Bladin277,278 a pioneer worker in the field of triazole synthesised the first
derivative in 1885 and an alternative name for the ring system was coined by
Andreocci279 a 'pyrodiazole' which is regarded as a member of a class of
compounds analogous to pyrrole.
1,2,4-Triazoles are not only known for their medicinal applications, but
also used as an analytical reagents280,281, dyes and photographic chemicals
and in the preparation of polymers.
(II)
s-Triazole or 1,2,4-Triazole
N
N
N
H
N
NH
N
v-Triazole or 1,2,3-Triazole
(I)
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N
N
H
N
NH
N
N
N
N
NH
SYNTHETIC ASPECTS
Several methods have been reported in the literatures for the preparation
of 1,2,4-triazoles shown as under.
1. Reid and Heindel282 reported that the reaction of aryl acid hydrazide with
CS2/KOH and hydrazine hydrate furnished triazoles.
2. Zhang Zivi et. al.283 prepared 1,2,4-triazoles by the addition reaction of
2 ,4-d ich lorophenoxyacet i c  ac id  hydraz ide  wi th  R.CO.NCS gave
aroylthiosemicarbazides. Cyclization of this in H2O in the presence of
alkaline catalyst gives triazoles.
3. Yan Shiquaing284 prepared by the treatment of Ferrocenecarboxylic acid
hydrazide with arylisothicyanate produced substituted thiosemicarbazides
which on cyclisation gave 3,4-disubstituted-4H-1,2,4-triazole-5-thiol.
Different types of methods285-287 for the preparation of 1,2,4-triazoles
documented in literaturte.
O
R
NH
NH2
KOH
CS2
O
R NH
NH
S
S   K
N
N
N
R
NH2
SHNH2.NH2.H2O
(III)
NH
O
O
R
NHO
O
NH
alkaline
catalyst
N
H
N
H
N
S
R
(IV)
Triazoles...
R = Aryl
R = Aryl
N
N
N
FC
SMe
Ph
(V)
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THERAPEUTIC IMPORTANCE
1,2,4-Triazole derivatives have been reported to be associated with diverse
biological activities. Drug molecules having 1,2,4-triazole nucleus with good
activity are listed below.
Triazoles...
4. Nefazodone
O
N
N
N
CH3
O
N
N
Cl
Antidepressant
N
N
N
CH3
O
O
H O
N
N
CH(CH3)2
Antifungal
3. Terconazole
N
N
N
O
OH
OH
OH
ONH2
Antiviral, Antiinfectious
N
N
N
OH
CH3
CH3
CH3
Cl
Cl
Plantgrowth regulator
2. Diclobutrazole1. Rifavirin
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3-Amino-1,2,4-triazole was the first triazole manufactured on large scale
from aminoguinidine formate useful as neutral herbicides288. Therapeutic
activity of 1,2,4-triazoles are listed below.
1. Antihypertensive289
2. Bacteriocidal290
3. Antiviral291
4. Antiinflammatory292
5. Fungicidal293
6. Herbicidal294
7. Antitumor295
8. Insecticidal & Acaricidal296
9. Anticonvulsant297
10. Diuretic298
11. Anticancer & antiHIV299
N
N
S
Br
N
N
CH3Cl
Sedative, Hypnotic
5. Brotizolam 6. Fluconazole
Antifungal
OH N
N
N
F
F
NN
N
Pesticide
Estrogen inhibitor
Antineoplastic
N
NN
N
N
N
N
N
O
P
S O
O
CH3
CH3
7. Letrozole 8. Triazophose
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12. Plant growth regulator300
13. Antimicrobial301
14. Antileishmanial302
1,2,4-Triazole derivatives have been used successfully in the control of
fungal infection303 and also as nematicidal304, eosinophilla305 inhibitors,
hypoglycemic activity306 and microbicides307 for plant protection.
Amir  Mohammad308 have prepared 1,2,4- t r iazole der ivat ives as
antiinflammatory agents. Shi Yan-Nian and co-workers309 have 2H, pyrazolo,
1,2,4-triazole as plant growth regulator. Bignon Eric et. al.310 have documented
N-triazolyl-2-indol carboxamides useful as CCK - A agonists. Lattmann Rene et.
al.311 have reported 3,5-bis-hydroxylphenyl-1,2,4-triazoles (VI) useful as
pharmaceutical chelators.
Slawinski312 have prepared triazole as potent cardiovascular agent. A
number of 1H-1,2,4-triazole313derivatives have been synthesised for their broad
spectrum of biological activities. Some of them were commerciallized as
agrochemical, fungicides, insecticides, herbicides and plant growth regulators.
Jautelat et. al.314 have reported 1,2,4-triazoles as 100% inhibitor of Erisyphe
graminis on barley. Sikorski315 have determined triazoles useful for inhibiting
cholesteryl ester transfer protein activity.
Triazoles...
(VI)
N
N N
OR2
R3
OR4
R5
R1
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Varvaresou Athanasia and co-workers316 have suggested indoyl-1,2,4-
triazole and reported them as antidepressant and antimicrobial agents. Baba
Alsuo et. al.317 documented triazole useful as antiheumatic agents. Laddi U. V
and co-workers318 have prepared triazoles for antiinflammatory activity,
ulcerogenic liability, antimicrobial and antitubercular agents. Sun-Qingyan et.
al.319 have determined triazoles (VII) and reported their antifungal activity.
Some new 1H,1,2,4-triazoles possessing antiviral (antiinfluenza virus),
antibacterial and antifungal agents synthesised by Sproula et. al.320 Jag Mohan
et. al.321 have synthesised thiazolo-triazoles and studied for their antimicrobial
activity.
Abdelal Ali et. al.322 have investigated some 1,2,4-triazole derivatives as
potential antitumor agents. Rollas Sevim et. al.323 have screened 1,2,4-triazoles
as antimicrobial and anticonvulsant agents. El.Sayed et. al.324 have reported
triazoles (IIX) as potent fungicides and bactericides.
Triazoles...
N
N
N
R
OH
F
F
(VII)
R = Aryl
N
N
N
SH N
N
Ar
O
X
NO2
NH2/Ph
(VIII)
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MariMakoto et. al.325 have synthesised water soluble triazoles as fungicides.
Ladawahetty et. al.326 have prepared triazoles as selective human GABA
receptor for the treatment of anxiety and enhancing cognition. Giorgia Pastorin
et. al.327 have documented 1,2,4-triazoles as adenosine receptor antagonist
and also as human A3 and A2B adenosine receptor. B. Shivarama Holla et.
al.328 have screened 1,2,4-triazoles as anticancer. Uesaka et. al.329 documented
triazoles as adrenergic α2C receptor antagonists.
Looking to the diversified pharamacological activity, it appeared of interest
to synthesise some 4-aryl triazoles, azomethines and 1,3,4-thiadiazolo triazoles
bearing triazole moiety, in order to achieving compounds having better
therapeutic importance. These study are described in following parts.
STUDIES ON TRIAZOLES
PART - I : STUDIES ON ARYLTRIAZOLE
PART - II : STUDIES ON AZOMETHINES
PART - III : STUDIES ON 1,3,4-THIADIAZOLO TRIAZOLES
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PART - I
STUDIES ON
4-ARYLTRIAZOLES
INTRODUCTION
Amongst the five membered nitrogen containing heterocycles, the position
of nitrogen atom on 1,2 and 4 position activates the ring and proved to be most
important pharmacological drugs. The scientists all over the world have focused
their attention to evaluate 4-Aryltriazole ring system (I).
SYNTHETIC ASPECTS
Several methods have been reported in the literatures for the preparation
of 4-aryltriazoles.
By the reaction of acid hydrazide with
(a) Carbon disulphide, Al. KOH under cyclisation with different amine,
hydrazine.
(b) Thiosemicarbazide derivatives followed by ring closure with NaOH.
THERAPEUTIC IMPORTANCE
4-Aryltriazoles have attracted considerable attention as they appeared of
interest to possess wide range of therapeutic activities. Different activity of 1,2,4-
triazoles have been already discussed.
N N
N
R
X SH
(I) R = Aryl
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Furthermore Chambers et. al.330 have investigated 4-aryl triazoles useful
in the treatment of neurogenerative disease. Pier et. al.331 repor ted as
irreversible antagonist at the A3, A2A adenosine receptor
332. Patel K. D. et.
al.333 have prepared triazoles (II) as antimicrobial agents.
Many co-workers have reported 4-aryl triazoles as aromatase-steroid
sulfatase inhibitors334, GSK-3 inhibitors335, anticancer336, fungicidal337,
antibacterial338, antiinflammatory339, PKB (Protein Kinase B) inhibitors340,
Herbicidal Agents341-343.
Recent ly Galcera et .  a l .344 have screened 4-aryl t r iazoles ( I I I )  as
somatostatin receptors. Other co-workers have studied activity of triazoles like
adenosine receptor antagonists345,346, ant icancer347, analgesic and
diuretics348 and in the treatment of diseases caused due to excess of metal349
in body. Heindel and co-workers350 have synthesised 4-aryl triazoles (IV) useful
as nitric oxide synthatase inhibitors.
With an aim to synthesise better therapeutic agents, we have investigated
some new 4-aryltriazole derivatives which have been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
MERCAPTO-4,N-ARYL-5-BENZYL-1,2,4-TRIAZOLES
Cl
Cl
Cl
OCH2
N N
N
R
Ph
(II) R = Aryl
N N
N
R1
S
R3
R2
N N
N
N
SHR
R
(III) (IV)
Aryltriazoles...
R
1
, R
2
, R
3
 = Aryl
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-4,N-
ARYL-5-BENZYL-1,2,4-TRIAZOLES
The growing potent literature of recent years demonstrates that the triazole
derivatives are useful as better therapeutic agents. These findings prompted us
to synthesise 3-mercapto-4,N-aryl-5-benzyl-1,2,4-triazoles. The synthesis of
triazole derivatives of type (IX) has been undertaken by heating potassium
phenyl acetic acid hydrazide dithiocarbamate with different aromatic amines.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry. In mass spectrometry m/z value indicates
the molecular weight, i.e. when R  = ρ-tolyl, molecular weight = 281, m/z=282
(m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
N N
N
SH
R
R = ArylType (IX)
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N N
N
SH
R
R NH2
CONH NH
S
S  K
+-
EtOH, KOH
CS2
CONH NH2
NH2NH2H2O
COOEt
EtOH
Conc. H2SO4
COOH
Type (IX) R = Aryl
REACTION  SCHEME
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-MERCAPTO-4,N-
ARYL-5-BENZYL-1,2,4-TRIAZOLES
(A) Synthesis of Ethylphenyl acetate351
Phenyl acetic acid (1.36 g, 0.01 M) in 25 ml ethanol and 1 ml conc. sulfuric
acid was refluxed for 15 hrs. and poured into ice. The product was isolated and
treated with sat. sodium bicarbonate solution. Yield 85%, b.p. 229
o
C.
(B) Synthesis of Phenylacetic acid hydrazide351
A mixture of Ethylphenylacetate (1.64 g, 0.01 M) and hydrazine hydrate
(0.5 g, 0.01 M) was heated for 6 hrs. and poured into ice. The product was
isolated and crystallised from water. Yield 80%, m.p. 184oC.
(C) Synthesis  o f  Potassium phenyl  acet ic  acid hydrazide
dithiocarbamate
A mixture of phenyl acetic acid hydrazide (1.5 g, 0.01 M), KOH (0.84 g,
0.015 M) and CS2 1.5 ml in absolute alcohol was stirred for 24 hrs. and poured
into ice. The product was isolated from diethyl ether.
(D) Synthesis of 3-Mercapto-4,N-(ρ-tolyl)-5-benzyl-1,2,4-triazole
A mixture of (2.5 g, 0.01 M) potassium salt and ρ-toludine (1.07, 0.01 M)
was heated upto evolution of H2S gas caused nearly 10 hrs., DMF was added
(20 ml) and contents were poured into ice. The crude product was filtered and
crystallised from ethanol. Yield 64%, m.p. 180oC. (Anal. Found : C, 68.26 H,
5.54; N, 14.86%; C16H15N3S Requires: C, 68.30; H, 5.57; N, 14.93%).
Similarly other 4-aryl triazoles were synthesised. The physical data are
recorded in Table No. 9
(E) Antimicrobial activity of 3-Mercapto-4,N-aryl-5-benzyl-1,2,4-
triazoles
Antimicrobial testing was carried out as described in Part - I, Section - I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 9
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IR SPECTRAL STUDY OF 3-MERCAPTO-4,N-(ρ-TOLYL)-5-BENZYL-1,2,4-TRIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2948.9 2975-2950 434
-CH3 C-H str. (sym.) 2860.2 2880-2860 "
C-H def. (asym.) 1433.0 1470-1435 "
C-H def. (sym.) 1380.9 1385-1350 "
Aromatic C-H str. 3078.2 3080-3030 435
C=C str. 1560.3 1585-1480 "
C-H i.p. def. 1091.7 1125-1090 "
1028.0 1070-1000 "
C-H o.o.p. def. 823.5 835-810 "
Triazole C=N str. 1656.7 1650-1600 434
C-N str. 1168.8 1220-1020 "
N-N str. 1008.7 1050-1010 "
S-H str. 2331.8 2400-2300 438
C-S str. 696.3 700-600 "
N N
N
SH
CH3
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PMR SPECTRAL STUDY OF 3-MERCAPTO-4,N-(ρ-TOLYL)-5-BENZYL-1,2,4-TRIAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 2.40 3H singlet Ar-CH3
2 3.64 2H singlet -CH2
3 6.90-6.94 2H multiplet Ar-Hc, Ar-He
4 6.95 Jgf=8.4 2H doublet Ar-Hgg'
5 7.16-7.20 3H multiplet Ar-Ha, Ar-Hb,
Ar-Hd
6 7.23 Jfg=8.4 2H doublet Ar-Hff'
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N N
N
SH
CH3
a
e
d
c
b
f
g
f'
g'
N N
N
SH
CH3m/z = 282 (m+1)
EXPANDED AROMATIC REGION
130
Comp.
No.
1
TABLE NO. 9 : PHYSICAL CONSTANTS OF 3-MERCAPTO-4,N-ARYL-5-BENZYL-1,2,4-TRIAZOLES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
9a C6H5- C15H13N3S 267 188 0.49 55 15.72 15.65
9b 4-COOH-C6H4- C16H13N3O2S 311 168 0.42 55 13.50 13.45
9c 4-Cl-C6H4- C15H12N3SCl 302 178 0.61 68 13.92 13.88
9d 3,4-(Cl)2-C6H3- C15H11N3SCl2 336 195 0.55 70 12.50 12.47
9e 4-F-C6H4- C15H12N3SF 285 191 0.56 60 14.41 14.36
9f 4-OCH3-C6H4- C16H15N3OS 297 181 0.47 55 14.13 14.11
9g 4-CH3-C6H4- C16H15N3S 281 180 0.75 64 14.93 14.89
9h 3-CH3-C6H4- C16H15N3S 281 223 0.59 60 14.93 14.90
9i 2-CH3-C6H4- C16H15N3S 281 170 0.45 54 14.93 14.87
9j 4-NO2-C6H4- C15H12N4O2S 312 198 0.67 58 17.94 17.90
9k 3-NO2-C6H4- C15H12N4O2S 312 207 0.61 64 17.94 17.88
9l 2-NO2-C6H4- C15H12N4O2S 312 164 0.58 63 17.94 17.91
*TLC Solvent System : Ethylacetate : Hexane (2 : 8)
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PART - II
STUDIES ON
AZOMETHINES
INTRODUCTION
Azomethine derivatives have been found to be potent drug in pharmaceutical
industries and possess a wide spectrum of biological activity. Azomethines are
also known as schiff bases and they are well known intermediate for the
preparation of azetidinone, thiazolidinone, formazan, arylacetamide and many
other derivatives. These are the compounds containing characteristic -C=N-
group.
Azomethines are obtained mainly by heating the aldehyde & aromatic
amine together. However, it is sometimes more convenient to work in a solvent
such as alcohol, dilute acetic acid or glacial acetic acid. Sometimes the reaction
is aided by trace of acid; in other cases the hydrochloride of the amines can be
used in the synthesis. In general schiff bases do not react further with either of
the reagent used for their preparation, as do most of the other types of simple
intermediates.
SYNTHETIC ASPECTS
Several methods352-355 for the preparation of azomethine derivatives are
documented in literature.
1. General account of the summary of reaction of aldehydes with amine.
Azomethines...
R H
O
+ R' NH2
R N
R'
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Azomethines...
R H
O
+ R' NH2
R NH
R'
OH
R NH
R'
OH
R N
R' + H2O
2. Imine formation involves two steps.
(a) Addition of the amine to the carbonyl group of the aldehyde gives
aldol. The aldol is rarely capable of isolation.
(b) The loss of water to give an imine (azomethine), this corresponds to
the "crotonaldehyde stage" of the aldol condensation.
THERAPEUTIC IMPORTANCE
Smalders et. al.356 documented some new azomethines like benzylidene
naphthylamine which reacts with HP (O) (OCH2CH2Cl)2 to give potential
antitumor reagent phosphonates. Nagamatsu et. al.357 have prepared some
azomethines (I) by the condensation of 4-mercapto-1H-pyrazolo [3,4-d]
pyrimidine-6(7H)-one with hydrazine hydrate to give (I), useful as xanthine
oxidase inhibitors.
Yadawe M. S. and Patil S. A.358 have prepared azomethines (II). which
were screened for their antibacterial and antifungal activities.
A series of 4-[5-(halophenyl)-2-fur furylidene]-amino-3-mercapto-5-
substituted-1,2,4-triazoles were synthesised by Holla B. et. al.359 and reported
their antibacterial activity.
(II)(I)
N
H
N
N
N
H
O
N
R' N R
R = alkyl, aryl
R' = H, Me
N
N N
SH
N
Me
N
NN
SH
N
Me
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Mehta R. H. et. al.360 have synthesised coumarin azomethine derivatives
and reported their antibacterial activity. Khalafallah A. and Hassan M. 361 have
suggested some styryl schiff's bases as potential antibacterial and antifungal
agents. Sharat El-Din and Nabaweya362 have described compound having good
antibacterial activity.
Chohan et. al.363 have reported azomethines of type (III), which have
been screened and compared for their antibacterial action against bacterial
species.
De, Biplab and co-workers364 have synthesised azomethines (IV) by the
condensation of (imidazolinylamino) pyrazole carboxaldehydes with arylamines.
Some of them were found to exhibit significant antibacterial and antifungal
activit ies. Deshmukh M. and Doshi A. 365 have synthesised some new
azomethines show good antimicrobial activity against test organism.
Wang, Yangang and co-workers366 have screened some azomethines
having good plant harmone activity. Das, and co-workers367 have prepared
schiff base of aminohydroxyguanidine (SB-ASHGS) & were tested for antiviral
activity against herpes simplex virus type 1 (HSV-1) and adenovirus type 5 (Ad5)
alone with other heterocyclic SB-AHGS. Solankee Anjani et. al.368 have
suggested addition of 3,4,5-trimethoxybenzaldehyde to 4-thiazolidinones resulted
in benzylidene derivatives having potential antibacterial activity.
Azomethines...
N
N
NH
N
N
R2
Me
HC
X
R1
O
Ph
(IV)
N
N
N X
X = O, S(III) R1 = H, Me R2 = H, Ph X = PhN,4-MeOC6H4N
,4-O
2
NC
6
H
4
N
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Ram Tilak et. al.369 have synthesised some schiff bases, thiazolidinones
∆2-triazolines and formazans bearing 2-chlorophenothiazines and screened
against carrageenin induced edema in albino rats. The thiazolidinones showed
promising antiinflammatory activity. Cascaval Alexandru; et. al.370 have
synthesised azomethine of type (V) which exhibited antipyretic properties.
Ali, Yousif et. al.371 have reported some schiff's base derivatives of glucose
contg. acetylenic bond were also prepared hydroxybenzaldehydes were first
converted to o-prop-2-ynyl-benzaldehyde followed by their condensation with
glucosamine. The compounds possess bactericidal activity. Pandeya V. et. al.372
have prepared schiff bases showing good activity against vibrio cholerae.
Omar and et. al.373 have described cyclocondensation of azomethines
having good antischistosomal activity. Pawar R. P. et. al.374 have synthesised
azomethines by the condensation of iodovanillin with different substituted
aromatic amines showing good antibacterial activity. A novel class of acetyl
ferrocene derived from schiff bases possess antimicrobial activity by Chohan
and co-workers375. Holla, B. S. et. al.376 have documented azomethine (VI)
bearing triazole moiety which possess good antibacterial activity. Ergenc and
Azomethines...
(VI) (VII) R = Aryl
N
NN
SH
N
Ar
R
CHN
N N
SH
N
Ar
O
N N
H
N
S
N
R
(V) R = H, Me, R1,R2 = H, Cl
OH
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N
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N
O
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CH3
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co-workers377 have synthesised azomethine derivatives (VII) showing antifungal
activity. Holla, B. S. et. al.378 have prepared Mannich bases of type (VIII) as
under.
B. Shivarama et. al.379 have synthesised azomethines which were found
to possess antibacterial and antiinflammatory activity. Pascal Rotheist et. al.380
have reported some new azomethines as antiparasitic agents. Adnan A. et. al.381
studied the antiinflammatory activity of some azomethines. Dimmock J. et. al.382
have suggested azomethines as cytotoxic agent.
Thus with an effort to capitalize the biological potential of the heterocyclic
system and to provide more interesting compounds for biological study, we have
undertaken the synthesis of azomethines bearing triazole moiety.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
4,N-SUBSTITUTED BENZALAMINO-3-BENZYL-5-
MERCAPTO-1,2,4-TRIAZOLES
Azomethines...
N
N
N
O
N
R
R1 S
NO2
R, R
1
 = Aryl(VIII)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4,N-SUBSTITUTED
BENZALAMINO-3-BENZYL-5-MERCAPTO-1,2,4-TRIAZOLES
Considerable evidence has been accumulated to demonstrate the wide
applications of azomethines and also have drawn the attention of chemists due
to diversified biological activities associated with it. In view of these findings, it
appeared of interest to synthesise newer azomethines with better potency.
Azomethines of type (X) have been prepared by the condensation of 3-mercapto-
4-N-amino-5-benzyl-1,2,4-triazole with different aromatic aldehydes in presence
of sulphuric acid.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. When R  =  1. 3 , 4 - d i m e t h o x y p h e n y l ,
molecular weight = 354, m/z = 355 (m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
N N
N
SH
N
R
N N
N
SH
NH2
R-CHO
H2SO4
R = ArylType (X)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4,N-SUBSTITUTED
BENZALAMINO-3-BENZYL-5-MERCAPTO-1,2,4-TRIAZOLES
(A) Synthesis of Potassium phenylaceticacid hydrazide dithiocarbamate
Part - I, Section - I(C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-benzyl-1,2,4-triazole
A mixture of (2.5 g, 0.01 M) potassium salt and hydrazine hydrate (0.75 g,
0.015 M) in 25 ml absolute alcohol was refluxed for 5 hrs. The reaction mixture
was poured onto crushed ice and treated with gla. acetic acid. The product was
filtered and crystallised from ethanol. Yield 65%, m.p. 140oC. (Anal. Found : C,
52.38 H, 4.84; N, 27.12%; C9H10N4S Requires: C, 52.41; H, 4.89; N, 27.16%).
(C) Synthesis of  4,N-(3,4-Dimethoxybenzalamino)-3-benzyl-5-
mercapto-1,2,4-triazole
A mixture of 3-mercapto-4,N-amino-5-benzyl-1,2,4-triazole (2.06 g, 0.01
M) and veratraldehyde (1.66 g, 0.01 M) in 25 ml absolute alcohol in presence of
sulphuric acid as a catalyst were refluxed for 10 hrs. The resulting mixture was
poured into ice and the product was isolated and crystallised from ethanol.
Yield 64%, m.p. 224oC. (Anal. Found : C, 60.96 H, 5.09; N, 15.76%;
C18H18N4O2S Requires: C, 61.00; H, 5.12; N, 15.81%).
Similarly other azomethines have been synthesised. The physical data are
recorded in Table No. 10
(D) Antimicrobial activity 4,N-Substituted benzalamino-3-benzyl-5-
mercapto-1,2,4-triazoles
Antimicrobial testing was carried out as described in Part - I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.
10
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IR SPECTRAL STUDY OF 4,N-(3,4-DIMETHOXYPHENYLAMINO)-3-BENZYL-5-
MERCAPTO-1,2,4-TRIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2968.2 2975-2950 434
-CH3 C-H str. (sym.) 2860.2 2880-2860 "
C-H def. (asym.) 1467.2 1470-1435 "
C-H def. (sym.) 1365.5 1385-1350 "
Aromatic C-H str. 3060.8 3080-3030 435
C=C str. 1573.8 1585-1480 "
C-H i.p. def. 1099.3 1125-1090 "
1070.0 1070-1000 "
C-H o.o.p. def. 825.5 835-810 "
Triazole C=N str. 1602.7 1650-1600 434
C-N str. 1332.7 1350-1200 "
N-H str. 1026.1 1050-1010 "
C-S str. 698.2 700-600 438
N N
N
SH
N
O CH3
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CH3
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PMR SPECTRAL STUDY OF 4,N-(3,4-DIMETHOXYPHENYLAMINO)-3-BENZYL-5-
MERCAPTO-1,2,4-TRIAZOLE
Internal Standard : TMS; Solvent : CDCl3+DMSO6 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.92 3H singlet Ar-OCH3
2 3.94 3H singlet Ar-OCH3
3 4.14 2H singlet -CH2
4 6.94 Jgh=8.1 1H doublet Ar-Hg
5 7.19-7.30 6H multiplet Ar-Ha-e, Ar-Hh
6 7.39 Jfh=1.5 1H doublet Ar-Hf
7 10.04 1H singlet CHi
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TABLE NO. 10  : PHYSICAL CONSTANTS OF 4-N-SUBSTITUTED BENZALAMINO-3-BENZYL-5-MERCAPTO-
1,2,4-TRIAZOLES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
10a C6H5- C16H14N4S 294 186 0.52 60 19.03 19.01
10b -CH=CH-C6H5- C17H14N4S 306 181 0.63 61 18.29 18.24
10c 2-Cl-C6H4- C16H13N4SCl 329 191 0.50 74 17.04 17.00
10d 3,4-(OCH3)2-C6H3- C18H18N4O2S 354 224 0.49 64 15.81 15.76
10e 4-OH,3-OCH3-C6H3- C17H16N4O2S 340 189 0.48 60 16.46 16.41
10f 4-OH-C6H4- C16H14N4OS 310 195 0.55 64 18.05 18.01
10g 3-OH-C6H4- C16H14N4OS 310 >250 0.59 58 18.05 18.02
10h 2-OH-C6H4- C16H14N4OS 310 211 0.62 55 18.05 17.98
10i 4-OCH3-C6H4- C17H16N4OS 324 205 0.65 71 17.27 17.22
10j 2-OCH3-C6H4- C17H16N4OS 324 178 0.73 54 17.27 17.21
10k 3-NO2-C6H4- C16H13N5O2S 339 177 0.60 66 20.64 20.61
10l 2-NO2-C6H4- C16H13N5O2S 339 170 0.64 65 20.64 20.59
*TLC Solvent System : Ethylacetate : Hexane (2 : 8) (10a-10l)
(3 : 7) (10c,10d,10e)
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PART - III
STUDIES ON
1,3,4-THIADIAZOLO
TRIAZOLES
INTRODUCTION
1,3,4-Thiadiazole derivatives have been found to be potent drug in
pharmaceutical industries and possess a wide spectrum of biological activities.
Thiadiazole ring system consists of one sulphur and two nitrogen atoms present
in a five membered ring. According to their position, thiadiazole system can be
classified as 1,2,3-thiadiazoles (I), 1,2,4-thiadiazoles (II), 1,3,4-thiadiazoles (III)
and 1,2,5-thiadiazoles (IV).
Fischer has described the 1,3,4-thiadiazoles in 1882, for the first time which
was further developed by Bush & co-workers.Due to wide range of therapeutic
activities,the compounds having thiadiazole nucleus have greatly accelerated
the rate of progress in the field of pharmaceutical.
The literature of 1,3,4-thiadiazoles has been extensively reviewed by
Sandstrom383 1947, Sherman384  1948,  Bambas385 1952.
SYNTHETIC ASPECTS
Literature survey reveals that several publications and patents386 described
the synthesis of 1,3,4-thiadiazoles as under.
N
N
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1. Q. Bano and co-workers387 have synthesised 6-phenylamino 1,3,4-
thiadiazoles.
2. M. K. Albrahim et. al.388 have synthesised thiadiazoles from hydrazinyl
chloride.
THERAPEUTIC IMPORTANCE
Extensive research has been carried out to enhance the activity and reduce
toxicity of thiadiazole drugs. Various thiadiazole derivatives have resulted in
many potential drugs and are known to exhibit a broad spectrum of biological
activity.
Miller et. al.389 have discovered 1,3,4-thiadiazole-2-sulphonamides and
this compound has been extensively investigated for its effect on salt excretion,
eye pressure and as anticonvulsant390. R. Gerike391 have prepared Cefazedone
(VII), a thiadiazole analog of cephalosporanic acid, useful as antibacterial agent.
Recently Kidwai Mazaahir et. al.392 have synthesised cephalosporin derivatives
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(IIX) by microwave irradiation using solid support and reported them as
antimicrobial agents.
Wang Zhong-Yi and co-workers393 have synthesised some 3,6-diaryl-5,6-
dihydro-triazolo [3,4-b]-1,3,4-thiadiazoles (IX) and documented thier in vivo
antibacterial and antifungal properties.
The manifold implications of 1,3,4-thiadiazoles are well proved by a large
number of patents available on it as therapeutic agents. Thiadiazole derivatives
are having numerous pharmacological activities like,
Thiadiazolotrialzoles...
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1. Insecticidal394
2. Antiviral395
3. CNS depressant396
4. Antibacterial397
5. Antifungal398,399
6. Hypoglycemic400
7. Antiinflammatory401,402
8. Antihypertensive403,404
9. Antitumor405
10. Antitubercular406
11. Antipyretic407
12. Anthalmentic408
El. Sayed et. al.409 have reported thiadiazoles (X) as potent fungicides
and bactericides.
Severa l  co-workers  have repor ted th iadiazole der ivat ives  having
fungicidal410, plant growth regulators411, insecticidal412, antibacterial413 and
metalloproteinase inhibitors414 activity. Karimian et. al.415 have prepared
thiadiazole as inhibitors of cysteine activity dependant enzyme. Zhang et. al.416
shown antimicrobial activity of thiadiazole derivatives where as Manjunath et.
al.417 reported antimicrobial and antiinflammatory activity (XI).
Thiadiazolotrialzoles...
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CONTRIBUTION FROM OUR LABORATORY
Parikh et. al. have used substituted thiadiazolinone418, benzthiazole and
s-triazine419,420, 4-pyridyl421 moieties at 5-position (Y) in 1,3,4-thiadiazole
ring system and at 2-position (X) was substituted aryl, amino and s-triazine422.
H. H. Parekh et. al. have synthesised 1,3,4-thiadiazole having dapson423,424,
b i s  moie ty  a t  5-pos i t ion (Y)  and benza lamino,  benzoy lamino and
sulphonamido425, aryl426 moiety substituted at 2-position (X). General structure
for above references are as under.
Thiadiazolotrialzoles...
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Thiadiazolotrialzoles...
Marc and co-workers427 have investigated thiadiazoles (XIII) as antitumor
agents. Nalan et. al.428 have prepard some thiadiazoles and reported as
anticancer. Some biological active thiadiazoles have synthesied by Pandey V. K.
et al.429. Ma, Zhong et. al.430 have screened thiadiazoles (XIV) as fungicides.
Many co-workers  have repor ted 1,3,4- th iadiazo le  der ivat ives  as
antitumor431, nicotinic α7 receptor
432 and antiinflammatory agents433.
In view of  the therapeut ic  act iv i t ies  of  1,3,4-thiadiazoles,  i t  was
contemplated to synthesise 1,3,4-thiadiazolo triazoles in search of agents
possessing higher biological activity with least side effects, which have been
described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
ARYL-4-BENZYL-1,2,4-TRIAZOLO [4,5-b]-1,3,4-
THIADIAZOLES
SECTION - II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
ARYL-4-BENZYL-2,3-DIHYDRO-1,2,4-TRIAZOLO
[4,5-b]-1,3,4-THIADIAZOLES
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(XIII) X, Y = H, F, Cl, Br, I (XIV) R = Aryl
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-BENZYL-
1,2,4-TRIAZOLO [4,5-b]-1,3,4-THIADIAZOLES
The study of 1,3,4-thiadiazoles have revealed that thiadiazole derivatives
are valuable drugs for various diseases. These observations led us to synthesise
1,3,4-thiadiazolo-triazoles of type (XI) by the cyclisation of 3-mercapto-4-N-
amino-5-benzyl-1,2,4-triazole with different aromatic acids in presence of
phosphorous oxychloride.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, When i.e. R  = ρ-tolyl, molecular weight = 306,
m/z = 307 (m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
N N
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N N
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151
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-BENZYL-
1,2,4-TRIAZOLO [4,5-b]-1,3,4-THIADIAZOLES
(A) Synthesis of Potassium phenylacetic acid hydrazide dithiocarbamate
Part - I, Section - I(C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-benzyl-1,2,4-triazole
Part - II, Section - I(B).
(C) Synthesis of 2-(ρ-Tolyl)-4-benzyl-1,2,4-triazolo [4,5-b]-1,3,4-
thiadiazole
A mixture of 3-mercapto-4,N-amino-5-benzyl-1,2,4-triazole (2.06 g, 0.01
M) and ρ-toluic acid (1.36 g, 0.01 M) in 20 ml phosphorous oxychloride were
refluxed for 10 hrs in oilbath. The resulting mixture was poured into ice and
neutralised with sodium bicarbonate. The product was isolated and crystallised
from ethanol. Yield 65%, m.p. 164oC. (Anal. Found : C, 66.59 H, 4.56; N,
18.26%; C17H14N4S Requires: C, 66.64; H, 4.61; N, 18.29%).
Similarly other 1,3,4-thiadiazolo-triazole derivatives have been synthesised.
The physical data are recorded in Table No. 11
(D) Antimicrobial activity 2-Aryl-4-benzyl-1,2,4-triazolo [4,5-b]-1,3,4-
thiadiazoles
Antimicrobial testing was carried out as described in Part - I, Section-
I(D). The zone of inhibition of the test solutions are recorded in Graphical
Chart No. 11
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IR SPECTRAL STUDY OF 2-(ρ-TOLYL)-4-BENZYL-1,2,4-TRIAZOLO-[4,5-b]-1,3,4-
THIADIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2956.7 2975-2950 434
-CH3 C-H str. (sym.) 2860.2 2880-2860 "
C-H def. (asym.) 1454.2 1470-1435 "
C-H def. (sym.) 1359.7 1385-1350 "
Aromatic C-H str. 3030.0 3080-3030 435
C=C str. 1492.8 1585-1480 "
C-H i.p. def. 1118.6 1125-1090 "
1029.9 1070-1000 "
C-H o.o.p. def. 812.0 835-810 "
Triazole C=N str. 1602.7 1650-1600 434
C-N str. 1311.5 1350-1200 "
N-H str. 1029.0 1050-1010 "
(overlapped)
C-N-C str. 1049.2 1070-1000 "
Thiadiazole C-S-C str. 605.6 720-570 "
N
N
N
S
N
CH3
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PMR SPECTRAL STUDY OF 2-(ρ-TOLYL)-4-BENZYL-1,2,4-TRIAZOLO-[4,5-b]-1,3,4-
THIADIAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 2.44 3H singlet Ar-CH3
2 4.48 2H singlet -CH2
3 7.27 2H doublet Ar-Hc, Ar-He
4 7.30-7.35 3H multiplet Ar-Ha, Ar-Hb,
Ar-Hd
5 7.45 Jgf=7.5 2H doublet Ar-Hgg'
6 7.73 Jfg=8.1 2H doublet Ar-Hff'
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TABLE NO. 11  : PHYSICAL CONSTANTS OF 2-ARYL-4-BENZYL-1,2,4-TRIAZOLO (4,5-b) -1 ,3 ,4-
THIADIAZOLES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
11a 2-0AC-C6H5- C18H14N4O2S 346 181 0.48 64 15.99 15.92
11b 4-NH2-C6H4- C16H13N5S 307 170 0.69 72 22.78 22.72
11c 2-NH2-C6H4- C16H13N5S 307 127 0.65 70 22.78 22.74
11d -CH=CH-C6H5- C18H14N4S 318 158 0.58 58 17.60 17.56
11e 4-Cl-C6H4- C16H11N4SCl 327 151 0.42 70 17.14 17.11
11f 2-F-C6H4- C16H11N4SF 310 138 0.55 65 17.65 17.59
11g 2-OH-C6H4- C16H12N4OS 308 155 0.61 60 18.17 18.14
11h 4-OCH3-C6H4- C17H14N4OS 322 166 0.54 54 17.38 17.32
11i 4-CH3-C6H4- C17H14N4S 306 164 0.50 65 18.29 18.26
11j 2-CH3-C6H4- C17H14N4S 306 178 0.52 61 18.29 18.23
11k -CH2-C6H5- C17H14N4S 306 145 0.58 72 18.29 18.25
11l -C5H4N C15H11N5S 293 144 0.60 64 23.87 23.84
*TLC Solvent System : Ethylacetate : Hexane (2 : 8) (11a-11l)
(3 : 7) (11a,11k)
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-BENZYL-
2,3-DIHYDRO-1,2,4-TRIAZOLO [4,5-b]-1,3,4-THIADIAZOLES
1,3,4-Thiadiazole derivatives are associated with broad spectrum of
pharmacological activity. In view of these findings, it appeared of interest to
synthesise newer 1,3,4-thiadiazole derivatives with better potency. 1,3,4-
thiadiazoles of type (XII) have been prepared by the condensation of 3-mercapto-
4,N-amino-5-benzyl-1,2,4-triazole with different aromatic aldehydes in presence
of ρ-toluene sulphonic acid.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, when i.e. R  = 3,4-dimethoxyphenyl, molecular
weight = 354, m/z=355 (m+1).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYL-4-BENZYL-
2,3-DIHYDRO-1,2,4-TRIAZOLO [4,5-b]-1,3,4-THIADIAZOLES
(A) Synthesis of Potassum phenylacetic acid hydrazide dithiocarbamate
Part - I, Section - I(C).
(B) Synthesis of 3-Mercapto-4,N-amino-5-benzyl-1,2,4-triazole
Part - II, Section - I(B).
(C) Synthesis of 2-(3,4-Dimethoxyphenyl)-4-benzyl-2,3-dihydro-1,2,4-
triazolo [4,5-b]-1,3,4-thiadiazole
A mixture of 3-mercapto-4,N-amino-5-benzyl-1,2,4-triazole (2.06 g, 0.01
M) and vera t ra ldehyde (1 .66 g ,  0 .01 M)  in  20 ml  dry  DMF and ρ−
toluenesulphonic acid (50 mg) were refluxed for 12 hrs. The resulting mixture
was poured into ice. The product was isolated and crystallised from ethanol.
Yield 74%, m.p. 144oC. (Anal. Found : C, 60.94 H, 5.08; N, 15.78%;
C18H18N4O2S Requires: C, 61.00; H, 5.12; N, 15.81%).
Similarly other 1,3,4-thiadiazolo triazole derivatives have been synthesised.
The physical data are recorded in Table No.12
(D) Antimicrobial activity 2-Aryl-4-benzyl-2,3-dihydro-1,2,4-triazolo
[4,5-b]-1,3,4-thiadiazoles
Antimicrobial testing was carried out as described in Part - I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 12
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IR SPECTRAL STUDY OF 2-(3,4-DIMETHOXYPHENYL)-4-BENZYL-2,3-DIHYDRO-
1,2,4-TRIAZOLO-[4,5-b]-1,3,4-THIADIAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C–H str. (asym.) 2968.2 2975-2950 434
-CH3 C-H str. (sym.) 2860.2 2880-2860 "
C-H def. (asym.) 1467.7 1470-1435 "
C-H def. (sym.) 1365.5 1385-1350 "
Aromatic C-H str. 3060.8 3070-3030 435
C=C str. 1512.1 1585-1480 "
C-H i.p. def. 1099.3 1125-1090 "
1070.4 1070-1000 "
Triazole C=N str. 1602.7 1650-1600 434
C-N str. 1330.8 1350-1200 "
N-H str. 1024.1 1050-1010 "
Thiadiazole C-S-C str. 584.4 720-570 "
N-H str. 3267.2 3450-3250 "
N-H def. 1571.9 1650-1580 "
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PMR SPECTRAL STUDY OF 2-(3,4-DIMETHOXYPHENYL)-4-BENZYL-2,3-DIHYDRO-
1,2,4-TRIAZOLO-[4,5-b]-1,3,4-THIADIAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position J. Value Relative No. Multiplicity Inference
No. (δ ppm) in Hz of Protons
1 3.95 3H singlet Ar-OCH3
2 3.95 3H singlet Ar-OCH3
3 4.17 2H singlet -CH2
4 6.92 Jgh=8.1 1H doublet Ar-Hg
5 7.25 1H singlet Ar-Ha
6 7.28-7.29 4H multiplet Ar-Hc, Ar-Hd,
Ar-e, Ar-Hh
7 7.31 1H doublet Ar-Hb
8 7.41 Jfh=1.6 1H doublet Ar-Hf
9 10.03 1H singlet CHi
10 11.14 1H singlet CHj
N
N
N
S
N
H
O
CH3
O
CH3
b
c
d
e
a
h
g
f
j
i
162
N
N
N
S
N
H
O
CH3
O
CH3
m/z = 355 (m+1)
EXPANDED AROMATIC REGION
163
Comp.
No.
1
TABLE NO. 12  : PHYSICAL CONSTANTS OF 2-ARYL-4-BENZYL-2,3-DIHYDRO-1,2,4-TRIAZOLO (4,5-b)-1,3,4-
THIADIAZOLES
Found
9
M.P.
oC
5
Yield
%
7
Calcd.
8
% of NitrogenMolecular
Formula
3
Molecular
Weight
4
Rf*
Value
6
R
2
*TLC Solvent System : Ethylacetate : Hexane (2 : 8) (12a-12l)
12a C6H5- C16H14N4S 294 158 0.54 71 19.03 19.00
12b -CH=CH-C6H5- C18H16N4S 320 132 0.59 73 17.49 17.43
12c 2-Cl-C6H4- C16H13N4SCl 329 128 0.65 65 17.04 17.01
12d 3,4-(OCH3)2-C6H3- C18H18N4O2S 354 144 0.71 74 15.81 15.78
12e 4-OH,3-OCH3-C6H3- C17H16N4O2S 340 185 0.68 64 16.46 16.42
12f 4-OH-C6H4- C16H16N4OS 310 150 0.50 70 18.05 18.03
12g 3-OH-C6H4- C16H16N4OS 310 164 0.61 61 18.05 18.01
12h 2-OH-C6H4- C16H16N4OS 310 161 0.49 65 18.05 17.99
12i 4-OCH3-C6H4- C17H16N4OS 324 178 0.62 69 17.27 17.22
12j 2-OCH3-C6H4- C17H16N4OS 324 165 0.74 64 17.27 17.24
12k 3-NO2-C6H4- C16H13N5O2S 339 140 0.69 60 20.64 20.61
12l 2-NO2-C6H4- C16H13N5O2S 339 135 0.78 68 20.64 20.59
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